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The cardinal climacteric symptoms of hot flushes and night sweats affect 24-93% of all women during the physiological
transition from reproductive to post-reproductive life. Though efficacious, hormonal therapy and partial oestrogenic
compounds are linked to a significant increase in breast cancer. Non-hormonal treatments are thus greatly appreciated.
This systematic review of published hormonal and non-hormonal treatments for climacteric, and breast and prostate
cancer-associated hot flushes, examines clinical efficacy and therapy-related cancer risk modulation.
A PubMed search included literature up to June 19, 2014 without limits for initial dates or language, with the search
terms, (hot flush* OR hot flash*) AND (clinical trial* OR clinical stud*) AND (randomi* OR observational) NOT review).
Retrieved references identified further papers. The focus was on hot flushes; other symptoms (night sweats, irritability,
etc.) were not specifically screened. Included were some 610 clinical studies where a measured effect of the
intervention, intensity and severity were documented, and where patients received treatment of pharmaceutical
quality. Only 147 of these references described studies with alternative non-hormonal treatments in post-menopausal
women and in breast and prostate cancer survivors; these results are presented in Additional file 1.
The most effective hot flush treatment is oestrogenic hormones, or a combination of oestrogen and progestins,
though benefits are partially outweighed by a significantly increased risk for breast cancer development.
This review illustrates that certain non-hormonal treatments, including selective serotonin reuptake inhibitors,
gabapentin/pregabalin, and Cimicifuga racemosa extracts, show a positive risk-benefit ratio.
Key points
 Several non-hormonal alternatives to hormonal therapy have been established and registered for the
treatment of vasomotor climacteric symptoms in peri- and post-menopausal women.
 There are indications that non-hormonal treatments are useful alternatives in patients with a history of breast and
prostate cancer. However, confirmation by larger clinical trials is required.
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Well-characterised primary symptoms associated with
the climacterium include hot flushes (HF), sweating,
insomnia, nervousness and irritability, palpitations,
changes in libido, dyspareunia, depression, musculoskel-
etal pain, vaginal pruritus and dryness, pain and/or
inflammation, and increased bone turnover (Burger et al.
2002; Crandall et al. 2011). These symptoms vary in fre-
quency and severity, and are presumed to be evoked by
the physiological decrease in ovarian function as women
transition from reproductive to post-reproductive life
(Kronenberg 1990; Nakano et al. 2012; Crandall et al.
2011; Hunter et al. 2012). In other patients, the same
symptoms may be caused by chemotherapy or surgery
relating to breast cancer or other malignancies. The
prevalence of the cardinal vasomotor symptoms, HF and
night sweating, varies between 24 and 93% in peri- and
post-menopausal women (Kronenberg 1990; Nakano
et al. 2012; Crandall et al. 2011; Hunter et al. 2012), and
is observed in more than 65% of breast cancer patients
(Adelson et al. 2005). Patients with chemotherapy-
induced ovarian insufficiency experience even more se-
vere symptoms than patients undergoing normal ageing
(Adelson et al. 2005; Carpenter et al. 1998), and the ef-
fect on the quality of life varies greatly among those
affected.
Even men experience HF during normal ageing,
evoked by gradually decreasing testosterone levels. One
Swedish survey found that 31% of non-castrated ageing
men reported HF and, of these, the quality of life was af-
fected in 50% (Spetz et al. 2003). Aggravated symptoms
are observed when testosterone concentrations decrease
rapidly, such as during anti-androgen treatment or after
orchiectomy for prostate cancer (Adelson et al. 2005).
About 63%-80% of post-orchiectomy prostate cancer pa-
tients complained of long-lasting HF (Charig & Rundle
1989; Karling et al. 1994; Schow et al. 1998). More than
48% of these patients complained of sustained flushes
5 years after onset, and more than 40% experienced
flushes even 8 years after castration (Karling et al. 1994).Aetiology
Though not fully understood, several authors propose that
the aetiology of HF is due to a changed thermoregulation
set point of the hypothalamus evoked by the abruptly-
lowered oestrogen levels during menopause (Adelson
et al. 2005; Kronenberg 1994). Other neuroendocrine hor-
mones (e.g., α-adrenergic mechanisms (Berendsen 2000;
Rosenberg & Larsen 1991)) may be involved in this dis-
turbance of temperature regulation. Oestrogen interacts
with neurotransmitters, such as norepinephrine and en-
dogenous opioids (Casper & Yen 1985; Rebar & Spitzer
1987), as well as serotonin (Berendsen 2000), and therebyalters the temperature regulation set point in the
hypothalamus.
Post-menopausal women show a diminished seroto-
nergic activity compared to pre-menopausal controls.
After oestrogen hormone replacement therapy, sero-
tonin activity becomes partly normalised (Blum et al.
1996; Gonzales & Carrillo 1993; Halbreich et al. 1995).
Serotonin 5-HT2A receptors play a key role in the devel-
opment of HF in the hypothalamus. These receptors are
up-regulated during oestrogen withdrawal (Biegon
1990). Blockage of 5-HT2A receptors by the 5-HT2,3 re-
ceptor blocker, mirtazapine, in post-menopausal women
reduced the frequency and intensity of HF (Waldinger
et al. 2000). On the other hand, activation of 5-HT2
receptors with m-chlorophenylpiperazine, a 5-HT2A:2C
receptor agonist, induced post-menopausal symptoms,
such as sweating and hot and cold flushes and palpita-
tions (Berendsen 2000) (and references cited therein).
The frequency and severity of HF secondary to medical
castration for advanced prostate cancer are reduced with
sertraline (Roth & Scher 1998). It has also been shown
that 5-HT1A, 5-HT1D and 5-HT7 receptors are also in-
volved in hypothalamic thermoregulation (Hedlund et al.
2003; Naumenko et al. 2011). Cimicifuga racemosa
extracts (CRE) bind to the serotonin receptors 5-HT1A,
5-HT1D and 5-HT7 (Burdette et al. 2003; Powell et al.
2008), and a part of its effect on HF may be mediated by
these receptors. In addition, oestrogen increases the
density of 5-HT2A receptors in the nucleus accumbens,
suggesting an effect of oestrogen withdrawal on mood
and may explain the onset of depressive symptoms in
menopause (Fink & Sumner 1996; Fink et al. 1996).
Treatment of climacteric symptoms with hormone
therapy
Different treatments have been established for climacteric
symptoms. For many years, hormone therapy (HT) using
oestrogen or a combination of oestrogen and progestins
was the gold standard. Much evidence exists that HT ef-
fectively reduces climacteric symptoms in women (as indi-
cated by a Cochrane meta-analysis of 24 randomised,
placebo-controlled trials (MacLennan et al. 2009)).
HT of climacteric symptoms and risk of breast cancer
As early as 1997, initial epidemiologic evidence showed
that HT may increase the risk of breast cancer. One
meta-analysis (Collaborative Group on Hormonal Fac-
tors in Breast Cancer 1997) of 51 epidemiologic studies
comparing data from 52,705 women with breast cancer,
and including 108,411 women without breast cancer,
revealed that the prevalence of breast cancer was signifi-
cantly increased in women using HT, and rose with dur-
ation of use. Several subsequent studies have confirmed
these data.
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trial that included 16,608 post-menopausal women was
prematurely terminated due to a significantly increased
risk of breast cancer development (nominal hazard ratios
(HR) 1.26 (95% confidence interval (95% CI) 1.00-1.59),
coronary heart disease (HR 1.29 (95% CI 1.02-1.63)),
stroke (HR 1.41 (95% CI 1.07-1.85)) and venous thrombo-
embolic disease (HR 2.11 (95% CI 1.58-2.82)) in the
hormone-treated arm (Rossouw et al. 2002).
Several other prospective und epidemiological studies
(Chlebowski et al. 2009; Collaborative Group on Hormo-
nal Factors in Breast Cancer 1997; Beral & Million
Women Study Collaborators 2003; Porch et al. 2002;
Weiss et al. 2002; Beral et al. 2002) confirmed these
findings; for a review, cf. (Collins et al. 2005).
In one large study combining data from a randomised
trial (n = 16,608) and an observational study (n = 41,449)
in the WHI population, temporal trends of breast cancer
diagnosis were analysed in groups who received daily
oestrogen plus medroxyprogesterone acetate or placebo
(Chlebowski et al. 2003). This study revealed that the
breast cancer risk increased steadily throughout the
mean follow-up of 5.6 years of the intervention period in
both study groups. However, at the end of the interven-
tion phase, hazard-ratio increased significantly for total
breast cancer (HR 1.24 (95% CI 1.02-1.50); p < 0.001))
and for invasive breast cancer (HR 1.24 (95% CI 1.01-
1.50); p = 0.003) in the oestrogen plus medroxyprogester-
one acetate group compared with placebo. Interestingly,
the elevated risk in the hormone-treated group de-
creased rapidly after stopping HT treatment, however, a
small and not significantly increased risk (HR 1.15
(95% CI 0.98-1.37)) was still present after 11 years of
follow up (Stevenson et al. 2011). The decrease was un-
related to mammography frequency, since this was un-
changed in the two groups. These results also concurred
with anecdotal evidence that withdrawal of HT alone led
to breast cancer regression (Powles & Hickish 1995). A
subgroup analysis showed that the breast cancer risk of
combined treatment with oestrogen and progestin in-
creased only in the subgroup of patients who received a
hormonal treatment prior to the study (adjusted HR 1.96
(95% CI 1.17-3.27), N = 4311) and not among the patients
who never used hormonal treatment before (HR 1.02
(95% CI 0.77-1.36); N = 12297) (Anderson et al. 2006).
In the Million Women Study (n = 1,084,110), current
HT users demonstrated a significantly increased relative
risk (RR): 1.66 (95% CI 1.58-1.75) for developing breast
cancer, whereas past users had no increased risk (RR
1.01 (95% CI 0.94-1.09)). The breast cancer risk in-
creased with duration of HT treatment and was more
pronounced with oestrogen-progestagen combinations
and, with respect to receptor status, were mixed and did
not show a significant increase in oestrogen receptor-positive cancers (Chlebowski et al. 2003). However, dose
or HT preparation (oral vs. transdermal vs. implant) did
not affect overall results (Beral & Million Women Study
Collaborators 2003). Other studies have shown diverging
results: a trend (p = 0.09) towards a lower risk (Prentice
et al. 2008) for breast cancer development and signifi-
cantly lower risk using monotherapy with conjugated
equine oestrogen alone compared to combination HT
(Ross et al. 2000; Saxena et al. 2010; Beral et al. 2011).
After publication of the WHI studies and the Million
Women Study, HT use decreased drastically worldwide
(Hersh et al. 2004; Canfell et al. 2008; Antoine et al.
2011). Notably, the lowered use was accompanied by a
significant decrease in breast cancer incidence in many
countries (Canfell et al. 2008; Ravdin et al. 2007; Canfell
et al. 2009) that was more evident in oestrogen-receptor
positive than in oestrogen-receptor negative cancers,
and in women older than 50 years of age (Ravdin et al.
2007). It was most prominent in countries with a high
absolute prevalence of HT use and could not be ex-
plained by changes in the mammography rate; cf. review
by Zbuk and Anand (Zbuk & Anand 2012). Using epide-
miologic data between the years 2000 (118,724 patients)
to 2007 (154,447) from Israel, Silverman et al. (Silverman
et al. 2011) could clearly discriminate between the effect
of HTand mammography rate for the risk of breast cancer
development and confirmed that the drop in HT fre-
quency caused a parallel drop in the breast cancer rate.
After cessation of HT, the increased risk of breast cancer
disappeared within 2 years (Narod 2011; Chlebowski et al.
2009; Beral et al. 2011).
Risk assessment of HT treatment in breast cancer patients
There is a need for medical management of climacteric
symptoms in cancer patients. In one survey, only 20.5%
of women being treated for breast cancer and suffering
from moderate to severe HF actually received any treat-
ment for their symptoms (Gupta et al. 2006). In an
earlier study in 190 women with breast cancer, the
prevalence of post-menopausal symptoms, such as HF,
was 65%; half of the women felt that they needed treat-
ment of these symptoms (Couzi et al. 1995).
The safety of HT in breast cancer patients was
reviewed in 20 studies by Antoine et al. (Antoine et al.
2007). Citing 10 prospective and two randomised studies
that were heterogeneous with respect to tumour charac-
teristics, prognostic factors and therapies, the authors
conclude that there are no reassuring data indicating
that HT is not without risks. Antoine also cited two
studies that showed decreased recurrence rates and two
others with lowered breast cancer mortality under HT
treatment (Antoine et al. 2007). Nevertheless, one rando-
mised study (HABITS trial, n = 434) showed that HT in-
creased the recurrence of breast cancer significantly
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Anderson 2004), and was therefore prematurely termi-
nated. The other randomised study (von Schoultz &
Rutqvist 2005) (Stockholm trial, n = 378) did not show any
difference in the cancer recurrence rate between HT and
the control group (relative HR 0.82; 95% CI 0.35-1.9).
Since the overall analysis of both studies revealed a signifi-
cantly greater risk of cancer recurrence in the HT group
(relative HR 1.8; 95% CI 1.03-3.1), the Stockholm trial was
likewise discontinued. The authors therefore concluded
that guidelines should advise against using HT in patients
with a history of breast cancer (Antoine et al. 2007).
Progestogens are effective in treating post-menopausal
symptoms: In one open (Erlik et al. 1981) and one pro-
spective randomised trial (Loprinzi et al. 1994a), more
than 80% of patients showed symptom improvement
after receiving megestrol acetate. The latter study also
included 66 men with prostate cancer who complained
of HF after androgen deprivation therapy. The degree of
symptom relief was similar in women and men. How-
ever, the safety of progestagens has not been established.
Treatment with synthetic compounds with partial
estrogenic activity
The minimum requirements for the clinical evaluation
of new products in the treatment of vasomotor symp-
toms have been defined by the Food and Drug Adminis-
tration (FDA) (FDA. U.S. Department of Health and
Human Services Food and Drug Administration 2003)
and the European Medicines Agency (EMA) (EMEA.
Committee for Medicinal products for human use
(CHMP) 2005). Besides the definition of outcome pa-
rameters and the methods of their evaluation, these
guidelines set standards requiring at least 12 weeks of
treatment for a randomised controlled clinical trial. This
considers the need for chronic treatment in this indica-
tion. Many of the academia-driven studies have been
performed with shorter treatment durations, and could
therefore be considered as providing merely supportive
evidence.
Tibolone
Tibolone is a synthetic steroid gonadomimetic with weak
oestrogenic, androgenic and progestogenic properties
(Baber et al. 2005). Its action has been described as a
selective tissue oestrogenic activity regulator (STEAR)
(Kloosterboer 2004), meaning that the amount of tissue en-
zymes (sulfatase, sulfotransferase, and 17β-hydroxysteroid
dehydrogenase) control the sum of active ligands for ster-
oid receptors, and may be responsible for tissue-specific ef-
fects. This concept may also explain certain discrepancies
from in vitro investigations: In vitro, tibolone exerts a pro-
liferative effect on an oestrogen–receptor-positive breast
cancer cell line (MCF-7), indicating a potential tumourpromoting effect (Lippert et al. 2002; Mueck et al. 2003).
In vivo, the proliferative effects of tibolone were investi-
gated in a randomised controlled trial by measuring the
content of the nuclear antigen Ki-67 (a proliferation
marker) in breast tissue biopsies after treatment with tibo-
lone, oestradiol/norethisterone acetate or placebo. No in-
crease in proliferation was seen in the tibolone or placebo
group, whereas a significant increase was observed in the
oestradiol/norethisterone acetate group (Conner et al.
2004). This was further investigated in a randomised,
placebo-controlled study in patients with oestrogen
receptor-positive primary breast cancer (Kubista et al.
2007). However, the treatment duration was only 14 days
and only a trend of a beneficial effect on proliferation was
observed.
Several studies have investigated tibolone as a potential
alternative to classical HT to reduce climacteric symptoms
(Landgren et al. 2002; Hammar et al. 1998). One inter-
national study conducted at 38 sites throughout Europe,
South Africa and Mexico with 485 women compared tibo-
lone (2.5 mg/d) to desvenlafaxine (100 mg/d) and placebo,
examining reduction in the number of HF. No difference
was noted between desvenlafaxine and placebo, but tibo-
lone significantly reduced the number of HF when com-
pared to placebo (p < 0.001), though there was a significant
increase in the number of tibolone subjects who experi-
enced bleeding (p < 0.024) (Bouchard et al. 2012).
In a large randomised study in 4,538 post-menopausal
women (Cummings et al. 2008), the effect of tibolone
was compared to placebo over 34 months with regard to
bone fracture, breast cancer development and cardiovas-
cular diseases. Compared to placebo, patients in the
tibolone group had a decreased risk of vertebral
fractures (p < 0.001), a decreased risk of non-vertebral
fractures (p < 0.01), and a decreased risk of developing
invasive breast (p = 0.02) and colon cancer (p = 0.04). On
the other hand, patients had an increased risk of stroke
(p = 0.02), for which the study was prematurely
terminated.
Tibolone’s symptom-alleviating effects have also been
demonstrated in breast cancer survivors in several clin-
ical studies (Baber et al. 2005; Kroiss et al. 2005). In one
prospective study, 103 post-menopausal women received
either tibolone, oestrogen plus medroxyprogesterone
acetate (i.e., HT) or placebo for one year (Marchesoni
et al. 2006). An increase in mammographic breast dens-
ity (as a surrogate marker for the development of breast
cancer) was observed in 45% after HT, but only in 2.3%
after tibolone treatment, and none in the placebo group
(Marchesoni et al. 2006; Greendale et al. 1999). How-
ever, a later study did not confirm these results (Kutlu
et al. 2004).
The safety and efficacy of tibolone have been studied in
great depth in the large LIBERATE (Livial Intervention
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erability) trial (Kenemans et al. 2009) in 3,148 women
with breast cancer and severe climacteric symptoms
due to treatment with tamoxifen, aromatase inhibitors,
gonadotropin-releasing hormone analogues or chemo-
therapy. Patients were randomised to receive either 2.5
mg/d tibolone or placebo. The primary endpoint was
the rate of breast cancer recurrence. After a median
follow-up of 3.1 years, patients in the tibolone group
had a significantly higher recurrence rate (p = 0.001,
HR 1.40 (95% CI 1.14-1.70)) than after placebo treat-
ment. Vasomotor symptoms and bone-mineral density
improved significantly with tibolone compared to pla-
cebo. From the finding that breast cancer recurrence
was more evident in patients with oestrogen-receptor
positive tumours, the authors concluded that tibolone
exerted an oestrogenic effect, and that its use in pa-
tients “with a known, past or suspected breast cancer
will remain contraindicated”. The LIBERATE trial bone
sub-study recruiting 763 women confirmed these re-
sults with the clarification that the increase in breast
cancer recurrence and tibolone use was higher in
women having normal bone mineral density than in
those with lower bone density (Bundred et al. 2012).
Non-hormonal alternatives to HT in the treatment
of climacteric symptoms
Some of the non-hormonal treatments (e.g., isoflavones
and vitamins) are marketed as food supplements in dif-
ferent countries (Europe, USA and Canada). Cimicifuga
racemosa is currently registered as a herbal medicinal
drug for the treatment of climacteric complaints in sev-
eral European countries (among them, Austria, Belgium,
Czech Republic, Denmark, Finland, Germany, Hungary,
Sweden, Switzerland, and UK) and Australia, South
Korea, South Africa. In some countries (such as USA)
Cimicifuga racemosa is used as a food supplement.
Paroxetine is registered in the USA for treatment of cli-
macteric complaints. Registration of desvenlafaxine was
rejected in the USA, and a New Drug Application
(NDA) was withdrawn by the manufacturer in Europe.
So far as we know, none of the other mentioned com-
pounds are registered for the treatment of menopausal
symptoms.
Literature search methodology
The search was carried out using the PubMed database
and included all literature up to June 19, 2014. No limits
were set for language. References cited in the papers re-
trieved were used to locate further papers. The following
search terms were used: (hot flush* OR hot flash*) AND
(clinical trial* OR clinical stud*) AND (randomi* OR ob-
servational) NOT review). This search revealed 609 clin-
ical studies. Only 147 of these references describedstudies with alternative, non-hormonal treatments for
HF in post-menopausal women and in breast cancer sur-
vivors, and these are presented in Additional file 1. All
effort was made to include statistical relevance (p values,
confidence intervals) whenever possible. It was noted
that, in many of the earlier studies (prior to 2000), this
informative criterion was less rigorously provided.Dopamine agonists
As mentioned above (Berendsen 2000; Rosenberg &
Larsen 1991), it is thought that α-adrenergic mecha-
nisms participate in the pathophysiology of HF. And as
is often the case in medicine, anecdotal reports pique
interest in the testing of a specific drug for a new indica-
tion. In this instance, hypertensive women being treated
with methyldopa, an α-adrenergic, centrally-active sym-
patholytic, reported improvement in HF symptoms. In
two randomised, placebo-controlled trials each lasting 4
weeks and involving 40 post-menopausal women each,
respectively (Nesheim & Saetre 1981; Andersen et al.
1986), significant improvement in HF symptoms was re-
ported. Another study expounded on this and compared
the following: bromocriptine (dopaminergic), liposom
(indirect dopaminergic), veralipride (antidopaminergic),
domperidone (a peripheral antidopaminergic) and pla-
cebo for treating vasomotor symptoms of menopause
(Zichella et al. 1986). As all active treatments proved ef-
fective, different pathways were postulated: A direct ac-
tion would be expected from dopamine, and direct and
indirect dopaminergic agents, while the antidopaminer-
gic drugs are thought to evoke a secondary dopamine-
like activity via the short-loop feedback exerted by
hyperprolactinaemia on tuberoinfundibular dopamine
neurons, or perhaps stimulation of the opioid system
(Zichella et al. 1986). Though improvement in HF was
seen, concerns about side effects (depression, anxiety,
decreased alertness, lethargy, dizziness, headaches, myal-
gia, etc.) led to other avenues being pursued.Adrenergic agonists
Clonidine, as a centrally-active antihypertensive and α2-
adrenoceptor agonist, seemed promising for the treat-
ment of HF.
Effects of oral clonidine were tested against no treat-
ment in 30 women where significant improvement in
HF frequency, severity and duration were noted (Chow
et al. 1993).
In a small randomised prospective double-blind study
(n = 29), transdermal therapy with clonidine (correspond-
ing to 0.1 mg/d) over 8 weeks significantly reduced the
number (80%, p < 0.04), severity (73%, p < 0.04) and dur-
ation (67%, p < 0.03) of HF, compared to 36%, 29% and
21% for placebo, respectively (Nagamani et al. 1987).
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controlled cross-over trials in post-menopausal patients,
significant improvements in the number, severity and
duration of HF were observed: In the first study (n =
100), patients received oral clonidine in doses ranging
from 0.025 to 0.075 mg b.i.d. for 4 weeks; effects were
then compared to placebo (Clayden et al. 1974). In the
second study (n = 66), patients received a fixed oral dose
of 0.050 mg clonidine or placebo twice daily for 4 weeks
(Edington et al. 1980), here however, more adverse
events (AEs) were observed in the clonidine vs. placebo
groups (dry mouth: 11 vs. 4, insomnia: 8 vs. 4). Since the
reduction in HF frequency was small although statisti-
cally significant, the authors concluded that clonidine
was a medication “that makes flushing more tolerable”.
The effect of low-dose oral clonidine therapy (up to
0.4 mg/day) for up to 4 weeks was further investigated
in several other small studies (n = 10-30); results showed
either a significant reduction in the number and severity
of HF (Laufer et al. 1982; Chow et al. 1993) or no effect
(Wren & Brown 1986), but again, in very small patient
numbers and thus of limited value.
Positive effects were confirmed in a larger randomised
double-blind cross-over study in 110 female breast can-
cer survivors receiving concomitant tamoxifen treatment
(Goldberg et al. 1994), where transdermal clonidine
(equivalent to a daily oral dose of 0.1 mg) or placebo
was given for 4 weeks. Clonidine therapy reduced HF
frequency (20% lower than baseline values, p < 0.0001)
and severity (10% lower than baseline values, p = 0.02),
but accompanied by more AEs (dry mouth, p < 0.001;
constipation, p < 0.02; itchiness under the patch, p < 0.01
and drowsiness, p < 0.05). Transdermal clonidine (corre-
sponding to 0.1 mg/d) was also studied in 70 male pros-
tate cancer survivors where no significant decrease in
HF was noted (p = 0.57) (Loprinzi et al. 1994b).
In a larger trial, the effects of oral clonidine were
assessed in 194 post-menopausal women with breast
cancer who were receiving tamoxifen treatment (Pandya
et al. 2000). After 8 weeks of treatment, frequency of HF
decreased by 38% in the clonidine group compared to
24% in the placebo group (p = 0.006); however, patients
receiving clonidine reported more sleep disturbances
(41% vs. 21%; p = 0.02).
In another double-blind, randomised phase III study
that compared clonidine and venlafaxine in 80 breast
cancer survivors, most still receiving endocrine treat-
ment, the primary end-point was defined as the fre-
quency of hot flushes after 4 weeks of treatment using
HF and other symptom questionnaires. HF frequency
was −7.6 HF for venlafaxine and −4.85 for clonidine
(p = 0.025). Four clonidine and six venlafaxine patients
discontinued due to side effects (Loibl et al. 2007). And
in another venlafaxine vs. clondine double-blind, cross-over study in 60 breast cancer survivors, clonidine showed
fewer side effects and a higher reduction in HF (55%)
when compared with venlafaxine (49%), though statistical
significance was not reached. Discontinuation due to side
effects was observed in 5/53 for clonidine, and in 14/59
for venlafaxine (p = 0.038) (Buijs et al. 2009).
In a recent double-blind, placebo-controlled trial, 102
patients with a history of breast cancer were randomly
assigned (2:2:1) to oral daily doses of either venlafaxine
75 mg, clonidine 0.1 mg, or placebo for 12 weeks
(Boekhout et al. 2011). Results from the average daily
HF scores were assessed both at the week 12 time point,
and over the entire 12 weeks. During week 12, hot flush
scores were significantly lower in the clonidine group
versus placebo (p = 0.03), but not significant between
venlafaxine and placebo (p = 0.07), though the median
HF scores were identical in the clonidine and venlafax-
ine groups at this point. However, over the course of the
12-week trial, there were significant differences between
both treatments and placebo (p < 0.001 for venlafaxine
vs. placebo; p = 0.045 for clonidine vs. placebo). Frequen-
cies of nausea (p = 0.02), constipation (p = 0.04), and se-
vere appetite loss were higher in the venlafaxine group.
Depending on the study, clonidine is either superior or
inferior to venlafaxine as an effective treatment in the
management of HF in patients with breast cancer,
though not without AEs, such as insomnia, constipation
or dry mouth. Other studies are discussed under
venlafaxine.
No information is yet available as to whether clonidine
treatment can modulate the risk of breast cancer recur-
rence. On one hand, in vitro studies from a group in
Argentina have demonstrated a proliferative effect (in-
crease in thymidine incorporation) of clonidine in MCF-
7 breast cancer cells (Vázquez et al. 1999), in the mouse
mammary tumour cell line MC4-L5 (Bruzzone et al.
2008) and in stromal fibroblasts (Bruzzone et al. 2011).
In a case-controlled study using data from 2,079 patients
who received clonidine treatment (Friedman et al. 2011),
a slight but not significant increase in breast cancer de-
velopment was observed (odds ratio (OR) 1.08 (95% CI
0.98–1.20)). Based on the widespread use of clonidine,
the lack of significant epidemiological data suggests that
these results are most likely without clinical relevance.
Gabapentin/pregabalin
The first evidence that gabapentin/pregabalin exerted a
beneficial effect on HF was reported in 2000 by Guttuso
(Guttuso 2000), based on results from six patients.
Hypothesised mechanisms of action in HF amelioration
are modulation of calcium currents and mitigation of
hypothalamic tachykinin activity (Baber et al. 2005).
In a further uncontrolled pilot study (Loprinzi et al.
2002a) in 24 post-menopausal women of whom 20 were
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mg/day. With four drop-outs due to AEs (e.g. light-
headedness and dizziness), the 16 remaining subjects re-
ported a mean reduction in HF frequency and score of
66% and 70%, respectively.
In a randomised, double-blind, placebo-controlled trial
in 59 post-menopausal women with seven or more HF
per day, the effects of 900 mg oral gabapentin on HF fre-
quency were assessed after 12 weeks of treatment.
Gabapentin evoked a 45% reduction in HF frequency
and a 54% reduction in the HF composite score com-
pared to the placebo response (29% (p = 0.02) and 31%
(p = 0.01), respectively). In an extension phase, patients
were studied in an open-label trial where the dose of
gabapentin could be increased up to 2700 mg/day, as
needed. Treatment with the higher dose showed a fur-
ther reduction of 54% and 67%, respectively. Common
AEs in the gabapentin group were somnolence (n = 6),
dizziness (n = 4) and rash with and without peripheral
oedema (n = 2), which were not observed in the placebo
group. Four patients in the gabapentin group withdrew
their consent and terminated participation because
of dizziness, rash, heart palpitations and peripheral
oedema, respectively. Two patients temporarily reduced
the gabapentin dose due to dizziness and sleepiness. In
the extension phase, two patients previously in the pla-
cebo arm withdrew from the study due to dizziness and
peripheral oedema (Guttuso et al. 2003).
In another randomised, double-blind, placebo-controlled,
parallel group trial including 60 women with post-
menopausal symptoms, the effect of gabapentin (titrated to
2400 mg/day) was compared to conjugated oestrogens
(0.625 mg/day) and placebo for the treatment of moderate-
to-severe HF (Reddy et al. 2006) with 20 women per arm.
Both active treatments showed a significant and compar-
able reduction in mean HF composite score vs. placebo
after 12 weeks of treatment: oestrogen (72%, p = 0.016) and
gabapentin (71%, p = 0.004). In the placebo group, the
mean HF composite score decreased by 54%. In the gaba-
pentin group, slightly more AEs of headache, dizziness and
disorientation were observed.
In one randomised trial (Loprinzi et al. 2007) including
118 patients having HF symptoms that were insufficiently-
controlled with antidepressant therapy alone (primarily
venlafaxine or paroxetine), adding up to 900 mg/d gaba-
pentin resulted in a 54% (95% CI, 34% to 70%) and 56%
(95% CI, 26% to 71%) median reduction in HF frequency
and score, which was not statistically better than gabapen-
tin treatment alone, 49% (95% CI 26% to 58%) and 60%
(95% CI, 33% to 73%), respectively.
In a randomised, double-blind, placebo-controlled trial
in 200 menopausal women, the effect of 3 × 300 mg
gabapentin on vasomotoric symptoms was studied over
4 weeks (Butt et al. 2008). Significant decreases forgabapentin over placebo were noted in both the HF
score (51.0% vs. 26.5%, p < 0.001) and frequency (45.7%
vs. 24.7%, p < 0.001) for the gabapentin vs. placebo
groups, respectively. However, gabapentin treatment was
accompanied by a significantly higher rate of AEs than
placebo in the first treatment week, but these later
abated (dizziness: 18% vs. 1%; unsteadiness: 14% vs. 1%,
and drowsiness: 12% vs. 1%).
In two recent randomised placebo-controlled trial in
60 and 50 menopausal women, the effect of gabapentin
on vasomotoric symptoms were further confirmed: In
the first study (Saadati et al. 2013), when given over 12
weeks, 900 mg gabapentin significantly decreased both
HF frequency and severity (both p < 0.001). In the sec-
ond study (Agarwal et al. 2014), the results were con-
firmed in 50 post-menopausal women after 12 weeks
treatment, which was then extended to 24 weeks. Im-
pressive reductions in HF frequency (59.1% and 60.6%)
compared to placebo were noted at 12 (p = 0.008) and
24 weeks (p = 0.005), and the composite score decreased
by about 80% already at 12 weeks, which continued until
the end of the study (both p = 0.001).
A different, gastrorententive galenic formulation of
gabapentin was studied in a large randomised, placebo-
controlled study in 600 menopausal patients (Pinkerton
et al. 2014), providing a continuous drug release in the
upper small intestine for 8 to 9 hours. Gabapentin was
given asymmetrically (600 mg in the morning and 1200
mg in the evening) over 12 weeks, after which the HF
frequency (p = 0.0007) and severity (p = 0.012) decreased
modestly, but significantly compared to placebo. These
effects were maintained up to 24 weeks (p = 0.0174 and
p = 0.0457, respectively). Slightly more (5%) women
under gabapentin than placebo withdrew because of AEs
(16.7% and 11.5%, respectively). Most common in the
start phase were dizziness (12.7% and 3.4%), headache
(9.3% and 8.1%) and somnolence (6.0% and 2.7%), which
levelled off to comparable values over the study period.
Another double-blind RCT (Loprinzi et al. 2010) was
performed using pregabalin to treat HF in 207 post-
menopausal women. Two doses (2×75 mg/d and 2×150
mg/d) of pregabalin were compared to placebo for a
treatment period of 6 weeks. The HF score decreased
significantly by 50%, 65% (p = 0.009) and 71% (p = 0.007)
for the placebo, 75 mg b.i.d. and 150 mg b.i.d. group,
respectively.
Breast cancer
In a pilot study involving 22 breast cancer survivors re-
ceiving tamoxifen therapy, HF were treated with 3×300
mg daily gabapentin for 4 weeks. HF duration decreased
by 73.6% (p = 0.027) frequency by 44.2% (p < 0.001), and
severity by 52.6% (p < 0.001). Four women dropped out
due to AEs (nausea, rash, somnolence), while 8/16
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response (Pandya et al. 2004).
A large study (Pandya et al. 2005) in 420 breast cancer
survivors (300 mg/d or 900 mg/d GP vs. placebo over 8
weeks) also confirmed the effect in this patient popula-
tion: After 8 weeks of treatment, only the 900 mg dose
showed a significant reduction in HF frequency (44%,
p < 0.0001) and severity (46%; p < 0.0001) versus 15%
and 15% in the placebo group. However, the study dur-
ation was too short to assess whether the treatment
modulated the risk of tumour recurrence.
In a smaller cross-over RCT (N = 66) Bordeleau et al.
(Bordeleau et al. 2010) showed that gabapentin (up to
900 mg/d) and venlafaxine (up to 75 mg/d) demon-
strated a similar 66% reduction in HF score in breast
cancer survivors (p < 0.001); 32% of patients preferred
gabapentin, while 68% venlafaxine. The latter showed
more nausea, appetite loss, constipation, and reduced
negative mood changes than gabapentin, whereas gaba-
pentin demonstrated more dizziness and increased appe-
tite compared with venlafaxine (all p < 0.05).
Prostate cancer
Two studies investigated the effect of gabapentin in pros-
tate cancer survivors undergoing androgen deprivation
therapy: In a double-blind, placebo controlled trial
(Loprinzi et al. 2009) in 223 men, slight to moderate and
dose-dependent effects on HF frequency and severity
could be demonstrated in a short-term study over 4 weeks.
Compared to baseline, HF frequency and score decreased
by 21.5 (95% CI: 11.3-30.9%) and 27.0% (95% CI: 12.1-
36.1%) after placebo and by 45.5% (95% CI: 31.1-50.6%)
and 44.4% (95% CI: 35.2-56.3%) after administration of
900 mg/d, respectively. Only in the highest dose could a
significantly greater reduction in HF frequency (p = 0.02)
compared to placebo be demonstrated. In an extension of
the above-cited study (Moraska et al. 2010), 147 patients
were either switched from placebo to gabapentin or con-
tinued gabapentin treatment for eight additional weeks
with doses of gabapentin titrated up to 900 mg/d. The
treatment was well tolerated. Effects of previous high dose
treatments were maintained and those of low dose and
placebo treatments were improved. The majority of the
patients opted to take a dose of 600 mg/d. However, no
data were obtained regarding the question of whether
gabapentin was able to modulate prostate cancer disease.
In summary, results from several randomised con-
trolled trials (RCTs) in post-menopausal women without
cancer (Loprinzi et al. 2002a; Guttuso et al. 2003; Reddy
et al. 2006; Loprinzi et al. 2007; Butt et al. 2008; Saadati
et al. 2013; Agarwal et al. 2014; Pinkerton et al. 2014;
Loprinzi et al. 2010) and in breast and prostate cancer
survivors (Pandya et al. 2004; Pandya et al. 2005;
Bordeleau et al. 2010; Loprinzi et al. 2009; Moraska et al.2010), gabapentin showed no or a slight effect at lower
doses (<900 mg/d GP) or moderate effects at higher
doses, ranging from 44% (Pandya et al. 2005) to 71%
(Loprinzi et al. 2010; Reddy et al. 2006). The study dura-
tions were, in general, short (4–8 weeks) except in three
studies (Guttuso et al. 2003; Reddy et al. 2006; Saadati
et al. 2013) that continued for 12 weeks and two studies
for 24 weeks (Agarwal et al. 2014; Pinkerton et al. 2014).
Antidepressant drugs
Various antidepressant drugs (e.g., selective serotonin re-
uptake inhibitors (SSRIs) and serotonin-norepinephrine
reuptake inhibitors (SNRIs)) have been studied to treat
post-menopausal symptoms. The rationale of using anti-
depressant drugs is two-fold: Firstly, many patients with
climacteric symptoms suffer from depressive symptoms
and secondly, antidepressant drugs acting on synaptic
serotonin concentrations may beneficially interfere with
the pathophysiology of HF (Burdette et al. 2003; Hedlund
et al. 2003; Naumenko et al. 2011).
Selective serotonin reuptake inhibitors (SSRI)
Paroxetine
In 2003, Stearns and colleagues performed a large
randomised, double-blind, placebo-controlled, parallel
group study in 165 post-menopausal women administer-
ing placebo or 12.5 mg/d or controlled-release 25.0 mg/
d for 6 weeks (Stearns et al. 2003). The mean HF fre-
quency (and median composite score) decreased by
37.8% (1.8), 62.2% (3.3) and 64.6% (3.2) in the placebo,
12.5 mg/d and 25 mg/d paroxetine groups, respectively.
Although not statistically significant, AEs (mainly head-
ache, dizziness, nausea, and insomnia) were predomin-
antly observed with the higher paroxetine dose. This
same group confirmed these results in 2005 in a double-
blind, cross-over, placebo-controlled study involving 151
post-menopausal women. Women received first paroxe-
tine (10 or 20 mg/d) or placebo for 4 weeks, and then
the other treatment option (Stearns et al. 2005). The 10
mg dose reduced the hot flush frequency and composite
score by 40.6% and 45.6% vs. 13.7% and 13.7% for pla-
cebo, respectively (p = 0.0006 and p = 0.0008) and 20 mg
paroxetine by 51.7% and 56.1% vs. 26.6% and 28.8% for
placebo (p = 0.002 and p = 0.004, respectively). While ef-
ficacy was similar with the two paroxetine doses, women
were less likely to discontinue the low dose paroxetine,
which was also associated with a significant improve-
ment in sleep compared to placebo (p = 0.01).
Simon et al. reported the results of two large RCTs in a
total of 1184 menopausal women (Simon et al. 2013). Both
studies evaluated the effect of 7.5 mg daily paroxetine or
placebo, one study (N = 614) over 12, the other (N = 570)
over 24 weeks. In the 12-week study, HF frequency de-
creased significantly more from baseline (−33% vs. -23.5%;
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p = 0.009). However, HF severity score decreased signifi-
cantly only at week 4 (-0.09 vs. -0.05; p = 0.0048) but not
at week 12 (−0.10 vs. -0.09; p = 0.2893). In the 24-week
study, HF frequency decreased significantly more from
baseline (−28.9% vs. -19.0%; p < 0.0001) at week 4, and at
week 12 (−37.2% vs. -27.6%; p = 0.0001. The severity score
decreased significantly at week 4 (−0.09 vs. -0.06; p =
0.0452) and week 12 (−0.12 vs. -0.07; p = 0.0114). Final re-
sults for HF frequency and severity at week 24 were not
provided.
In 2013, Huang et al. (Huang et al. 2013) compared
paroxetine alone to paroxetine plus isopropanolic Cimi-
cifuga racemosa extract. Results from the Kupperman
(HF frequency and severity) and Hamilton depression
scales (HAMD) for the combined treatment were super-
ior with the combined treatment vs. paroxetine alone
(p < 0.01 and p < 0.05, respectively).
Breast cancer In 2000, Stearns and colleagues investi-
gated the effect of paroxetine in an observational pilot
study in 30 women with prior breast cancer over a treat-
ment period of 5 weeks at a dose of 10 mg/day for one
week, followed by 20 mg daily (Stearns et al. 2000). The
HF frequency was reduced by 67% and severity by 75%
(95% CI: 56%-79% and 66%-85%, respectively). Though
somnolence was observed in four patients leading to
drug discontinuation in two patients and likewise dose
reduction in two, there was a statistically significant im-
provement in depression, sleep disturbances, anxiety,
and quality of life scores.
Sertraline
In a double-blind, placebo-controlled, crossover trail in
102 menopausal women, sertraline 50 mg/d or placebo
was given over 4 weeks (Gordon et al. 2006). The num-
ber of hot flushes was significantly lower during sertra-
line treatment than placebo (p = 0.002): mean reduction
for the difference of 2.8 (95% CI 0.8-4.9; p = 0.007 during
daytime and 2.3 (95% CI 0.3-4.2; p = 0.03) during night-
time. The severity of hot flushes was not significantly
different between the treatments, but there was a signifi-
cant improvement in HF score (p = 0.001) on sertraline.
However, although significant, the overall benefit was
comparatively small.
No significant effect in alleviating HF frequency and in-
tensity better than placebo was found in a blinded,
placebo-controlled RCT involving 99 menopausal women
taking 50 or 100 mg sertraline daily for 6 weeks (Grady
et al. 2007). Inconclusive results were observed in a
further placebo-controlled RCT in 102 women where HF
symptoms and severity score improved over nine weeks in
one-third of the women, one-third showed no change, and
one-third worsened (Kerwin et al. 2007). In anotherplacebo-controlled RCT in 44 menopausal women (Aedo
et al. 2011), a higher percentage of patients (p = 0.01)
showed a symptomatic improvement of climacteric symp-
toms (e.g., 35.3% placebo and 81.3% sertraline).Breast cancer Two studies investigated sertraline in
women at high risk of, or having, breast cancer and on ad-
juvant tamoxifen therapy. Kimmick studied 62 women
who received either 50 mg sertraline/day or placebo for 6
weeks in a randomised, double-blind, cross-over design.
Treatment effects were only small: a 50% decrease in HF
frequency was observed in 36% of the sertraline patients
versus 27% receiving placebo (p = 0.7); (Kimmick et al.
2006). Wu (Wu et al. 2009) compared 25–100 mg/d vs.
placebo in 65 women who had either had, or were at high
risk for, breast cancer in a 6-week study (4-week treatment
phase). No significant differences were noted in either the
HF frequency or severity score between the groups.
In five case reports, Roth et al. (Roth & Scher 1998)
showed sertraline improved HF symptoms in prostate
cancer survivors who were also treated for concomitant
depression.Fluoxetine
In a placebo-controlled, double-blind study with a
follow-up period of 36 weeks, 150 healthy women with
menopausal symptoms were randomised into three
groups receiving placebo, fluoxetine, or citalopram
(Suvanto-Luukkonen et al. 2005). The initial 10 mg SSRI
doses (for fluoxetine and citalopram) increased to 20 mg
after 4 weeks and to 30 mg after 24 weeks. The main
outcome measures were HF frequency and Kupperman
index. No significant differences were observed in the
number of HF or severity index between placebo and
both SSRIs. The authors concluded that citalopram and
fluoxetine cannot be recommended for treating meno-
pausal complaints when vasomotor symptoms are the
primary problem.
In 2007, Oktem and colleagues compared 20 mg fluox-
etine with 40 mg Cimcifuga racemosa extract (CRE) in
120 menopausal women. After 24 weeks, the HF symp-
tom score were significantly reduced in the CRE group
(85% vs. 62%), and night sweats were likewise fewer with
CRE (both p < 0.01).Breast cancer A modest treatment effect was obtained
in 81 female breast cancer survivors. Patients were
treated with fluoxetine, 20 mg daily, or placebo over 4
weeks in a randomised, double-blind. cross-over design
(Loprinzi et al. 2002b) and demonstrated a 50% decrease
in HF score in the fluoxetine versus 36% in the placebo
arm (p = 0.02).
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In a placebo-controlled, double-blind study (cf, Sec-
tion Fluoxetine, (Suvanto-Luukkonen et al. 2005)), no
significant differences were observed in the number of
HF or severity index among citalopram, fluoxetine and
placebo.
More positive, dose-independent results were obtained
in another placebo-controlled trial involving 254 post-
menopausal women and 10, 20, or 30 mg/d citalopram
(the same dose range as in the study above (Suvanto-
Luukkonen et al. 2005)) given for 6 weeks and compared
to placebo (Barton et al. 2010). From baseline, reduc-
tions in HF frequency (46%, 43% and 50%, p ≤ 0.001)
and mean HF scores (49%, 50%, 55%, p ≤ 0.002) for the
respective increasing citalopram were superior to pla-
cebo (20% and 23%, respectively). Citalopram was well-
tolerated without any significant AEs.
Breast cancer In a four-week study, citalopram was in-
vestigated in 26 breast cancer survivors at doses of 10
mg during week 1, and 20 mg for weeks 2–4. A 58% re-
duction in HF frequency and a 64% reduction in HF
score from baseline were reported (Barton et al. 2003).
Escitalopram
In a small, uncontrolled pilot study in 25 menopausal
women, the effect of escitalopram was assessed at doses
of 10–20 mg/d (flexibly dosed for 8 weeks) in treating
HF. Women reported a significant decrease in HF fre-
quency (52.2%) and severity (53.8%) from baseline (both
p = 0.0001). With a responder being defined by at least a
50% decrease in HF frequency (Defronzo Dobkin et al.
2009), 16 patients were treatment responders, with an
average decrease of 55%.
These results were partly contradicted in two small
(N = 16 and N = 26) double blind, placebo-controlled
pilot studies (Freedman et al. 2011). Escitalopram was
given at a dose of 10 mg/d (study 1) or 20 mg/d (study
2) over 8 weeks. Escitalopram at 10 mg or 20 mg/day
was not effective in treating menopausal HF.
Expanded results from one randomised, double-blind,
placebo-controlled, parallel arm trial for 8 weeks in 205
women with menopausal symptoms reported the efficacy
and tolerability of 10–20 mg/day escitalopram on HF
frequency, severity and bother (Freeman et al. 2011;
Carpenter et al. 2012; Ensrud et al. 2012). At baseline,
HF frequency was 9.78/day (SD 5.60) and, at week 8,
was significantly less in the escitalopram group versus
placebo (−4.60 vs. –3.20; p = 0.004). In the escitalo-
pram group, 55% (versus 36% in the placebo group)
reported ≥50% decreases in HF frequency (p = 0.009),
and significant decreases in HF severity were likewise
noted (p = 0.003). New complaints reported by >10%
in the escitalopram group included dizziness/light-headedness (14%), vivid dreams (13%), nausea (11%)
and hyperhydrosis (11%). Some 4% (7 escitalopram, 2
placebo) discontinued the study due to side effects.
Venlafaxine
After the exploitation of the SSRIs (e.g., paroxetine, ser-
traline, fluoxetine, citalopram and escitalopram) in treat-
ing vasomotor symptoms, the SNRIs (e.g., venlafaxine,
desvenlafaxine) were put to the test. One study reported
on 80 post-menopausal patients who were randomised
to receive either placebo or 37.5 mg extended-release
daily venlafaxine for one week, followed by 11 weeks of
75 mg venlafaxine. Although there was a trend toward
lower HF severity scores in the treatment group, the dif-
ference between treatments did not reach significance
(p = 0.25). Three AEs, dry mouth, sleeplessness, and de-
creased appetite, were significantly more frequent in the
venlafaxine group (Evans et al. 2005).
Loprinzi et al. compared two doses of oral venlafaxine
(37.5 mg/d and 75 mg/d) to i.m. medroxyprogesterone
acetate (MPA) in 218 post-menopausal women. MPA
was superior in all aspects, including lower toxicity: A
50% decrease in HF frequency was achieved by 46% in
the VEN group, and 74% in the MPA group; further-
more, a 55% decrease in the HF score was noted for
VEN, while this result was 79% for MPA (all p < 0.0001)
(Loprinzi et al. 2006).
Breast and prostate cancer In spite of genetic varia-
tions among patients, it has been shown that venlafaxine
is a weaker inhibitor of cytochrome P450 2D6 (CYP2D6)
than paroxetine, and thus only slightly reduces plasma
concentrations of endoxifen, the potent tamoxifen me-
tabolite (Pritchard 2010) (This is discussed in further de-
tail under 4.2, Safety of Antidepressants in Patients with
a History of Breast Cancer, and 4.2.3, Interactions with
Tamoxifen). Extrapolating, venlafaxine could thus poten-
tially be preferable to SSRIs in the treatment of cancer
survivors suffering from HF.
Loprinzi tested this hypothesis using velafaxine in
breast (82%) and prostate cancer survivors (18%). After
4 weeks of treatment, 12.5 mg b.i.d. venlafaxine was
shown to be effective in reducing - by at least half - the
frequency of vasomotor symptoms in 54% of patients;
and 58% reported a median 55% reduction in the HF
score (95% CI 22-71%). Three patients terminated par-
ticipation – two due to AEs (decreased concentration,
depression, nausea, dry mouth, fatigue, and sleepiness)
and 1 switched treatment to megestrol acetate (Loprinzi
et al. 1998).
Carpenter tested venlafaxine in breast cancer survivors
in two sequential, double-blind, placebo-controlled
cross-over trials using low, 37.5 mg/d (n = 57) and high
doses, 75 mg/d (n = 20) (Carpenter et al. 2007).
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HF frequency (42% and 25% (both p = 0.001), respect-
ively) and severity (7% and 27% (both p < 0.001), respect-
ively). This study further observed that, when at least a
50% relief in physiological hot flashes was achieved, an
improvement in secondary outcomes, such as quality of
life parameters, including sleep, decreased fatigue, etc.
was correspondingly noted. The authors proposed using
this 50% threshold as a standard for evaluating other
pharmacological and/or behavioural therapies.
Similar to the study of Loprinzi cited above (Loprinzi
et al. 1998), positive results (38% reported at least a 50%
decrease in HF frequency, and 63% reported a median
decrease of 54% in the HF score) were noted in another
uncontrolled pilot study among 23 androgen-deprived
prostate cancer survivors using 12.5 mg venlafaxine
b.i.d. (Quella et al. 1999).
Loprinzi’s group confirmed these findings in a larger
double-blind, placebo-controlled study in 229 breast
cancer survivors by investigating the dose-dependence of
venlafaxine’s therapeutic effects (Loprinzi et al. 2000).
After a baseline assessment week, venlafaxine treatments
started at 37.5 mg daily and gradually increased to 75
mg or 150 mg daily for four weeks. Median HF frequen-
cies and scores were reduced from baseline by 19 and
27% (placebo); 30 and 37% (37.5 mg); 46 and 61%
(75 mg); and 58 and 61% (150 mg) (all p < 0.001). Ad-
verse effects (dry mouth, decreased appetite, nausea, and
constipation) were significantly higher compared to pla-
cebo in the 75 and 150 mg venlafaxine groups.
Three double-blind studies (Loibl et al. 2007; Buijs
et al. 2009; Boekhout et al. 2011), previously cited in the
clonidine section, compared various doses of venlafaxine
and clonidine in breast cancer survivors; results from
these studies were inconclusive viz. efficacy, but venla-
faxine tended to have more AEs. And in another study
that compared venlafaxine to gabapentin in 66 breast
cancer survivors, venlafaxine showed similar efficacy but
again more AEs (Bordeleau et al. 2010).
Contrasting results were found in one double-blind,
placebo-controlled RCT in 120 prostate cancer survi-
vors. Venlafaxine, at a dose of 75 mg/d, given either
together with milk protein or with 160 mg/d soy isofla-
vones showed no significant effect of HF frequency or
severity when compared to placebo plus milk protein or
160 mg/d soy isoflavones (Vitolins et al. 2013).
In conclusion, though some studies dispute venlafaxine’s
efficacy (Evans et al. 2005; Vitolins et al. 2013) several
other studies suggest a beneficial effect of venlafaxine in
the treatment of post-menopausal vasomotor symptoms,
also for breast and prostate cancer survivors, either alone
(Loprinzi et al. 1998; Carpenter et al. 2007; Quella et al.
1999), or against placebo (Loprinzi et al. 2000), or com-
pared to another active compound (Loprinzi et al. 2006;Loibl et al. 2007; Buijs et al. 2009; Boekhout et al. 2011;
Bordeleau et al. 2010). However, the treatment duration of
each of these studies was too short to investigate a poten-
tial increase in breast cancer recurrence. In addition to the
AEs cited in these studies that have led to certain patients
discontinuing the trial associated with venlafaxine (e.g.,
hypertension, decreased appetite, nausea/vomiting and
constipation, sleeping problems, and sexual disturbances),
breast enlargement is also a concern with this drug
(Amsterdam et al. 1997) and is discussed below under
Safety of Antidepressants in Patients with a History of
Breast Cancer.
Desvenlafaxine
Desvenlafaxine (O-desmethylvenlafaxine) is the active
metabolite of venlafaxine, and was studied in five large
randomised, placebo-controlled trials (Speroff et al.
2008; Archer et al. 2009a; Archer et al. 2009b; Bouchard
et al. 2012; Pinkerton et al. 2013) involving 2,582 post-
menopausal patients for at least 12 weeks. All but one
(Bouchard et al. 2012) of these studies showed a signifi-
cant beneficial effect in treating vasomotor symptoms.
However, none of these studies were performed in breast
cancer survivors. Although the drug was approved as an
antidepressant in the USA and Canada, the EMA did
not approve desvenlafaxine for the treatment of major
depression or menopausal complaints and the manufac-
turer therefore withdrew the European applications for
both indications (EMEA 2014).
Mirtazapine, moclobemide and bupropion
Mirtazapine treatment (15–30 mg/d) for HF was seren-
dipitously discovered in two depressed patients with
post-menopausal complaints (Waldinger et al. 2000).
Since HF and perspiration completely disappeared after
one week of treatment, medication use was extended to
two more patients without clinical signs of depression
but with the same climacteric symptoms. The authors
postulated that the 5-HT2A blocking properties may ac-
count for the effect on HF. In a single-arm pilot study in
22 women (Perez et al. 2004), 59% with breast cancer of
whom 9% and 45% were on raloxifene or tamoxifen
treatments, respectively, patients received incremental
doses of mirtazapine (7.5 (wash-in phase), 15 or 30 mg/
day). At the end of the 4-week treatment, the median
frequency and severity of HF decreased substantially by
52.5% and 59.5%, respectively. Similar results were ob-
tained in another uncontrolled trial in 40 breast cancer
survivors receiving 30 mg/d mirtazapine over 12 weeks
(Biglia et al. 2007). A 55.6% reduction in HF frequency
(p < 0.05) and 61.9% reduction in HF score relative to
baseline (p < 0.05) were observed. Seven patients discon-
tinued the study due to side effects, mostly somnolence.
However, to date, no randomised clinical trials have been
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adequately assessed.
There are also individual studies investigating two
other anti-depressants, bupropion and moclobemide, in
treating vasomotor symptoms. There have been anec-
dotal observations that bupropion, used for nicotine de-
pendence and depression, can relieve HF symptoms. A
pilot study lasting 4 treatment weeks was carried out in
21 patients, including breast and prostate cancer survi-
vors, who built up to a 300 mg bupropion daily dose.
Results showed that there was no significant reduction
noted over that which would be expected from placebo
(Perez et al. 2006).
Two different doses of moclobemide, 150 mg or 300
mg/d, were tested against placebo for 5 weeks in 30 post-
menopausal women. The lower dose of this reversible, se-
lective inhibitor of monoamine oxidase-A reduced the HF
severity score by 69.8%, compared to 35.0% in the higher
dose and 24.4% with placebo (Tarim et al. 2002).
Safety of antidepressants in patients with a history of
breast cancer
Prolactin and carcinogenesis
Certain antidepressant drugs modulate prolactin levels.
Serum prolactin levels were investigated in 70 psychi-
atric patients where it was noted that patients on imipra-
mine or amitriptyline treatment showed consistently
higher prolactin levels compared to untreated controls
(Turkington 1972). Prolactin is mitogenic, stimulates
proliferation and suppresses apoptosis in breast and
prostate cancer cells (Harvey et al. 2006) and is therefore
important in the development of treatment-resistance in
breast cancer cells (Carver et al. 2009).
Evidence from preclinical and clinical data show that
elevated prolactin levels cause proliferation of breast tis-
sue and result in breast enlargement, which may be
markers for an increased risk of breast cancer develop-
ment and important factors in the carcinogenicity of
mammary tissue (Ingram et al. 1990; Arendt et al. 2011;
Harvey et al. 2006; Clevenger et al. 2009; Carver et al.
2009). Breast enlargement was investigated and found in
39% of 59 women who received chronic SSRI or venla-
faxine treatment for more than 8 weeks for depression
(Amsterdam et al. 1997). Mammoplasia was reported in
64% of paroxetine-, 25% fluoxetine-, 25% sertraline- and
11% venlafaxine-treated patients. In the paroxetine
group, a significant (p < 0.01) increase in prolactin serum
concentrations was observed compared to pre-treatment
values. Post-menopausal women with elevated plasma
prolactin levels have a significantly higher risk of breast
cancer (Hankinson et al. 1999). Several other reports on
prolactin-related gynaecomastia, galactorrhoea, mastal-
gia or breast enlargement after tricyclic antidepressants,
SSRIs and venlafaxine (Kropp et al. 2004; González et al.2000; Bronzo & Stahl 1993; Bonin et al. 1994; Scurlock
& Meehan 1996; Bonin et al. 1997), have confirmed
these findings.
A mechanistic explanation of the prolactin increase
after treatment with tricyclic antidepressants and SSRIs
was provided by the finding that 5-HT neurons are be-
lieved to maintain a tonic inhibitory influence on dopa-
mine function (Bonin et al. 1997). In addition to this
indirect effect, tricyclic antidepressants and fluoxetine
bind directly to intracellular, growth regulatory histamine
receptors that are associated with anti-oestrogen binding
sites. With this background in mind, the effects of amitrip-
tyline and fluoxetine on tumour growth were investigated
in rodents (Brandes et al. 1992), at concentrations corre-
sponding to the treatment of human depression. Tumour
latency decreased by 30-40% and frequency increased 2-
fold in the DMBA (7,12-dimethylbenz[a]anthraene) model
for chemically-induced breast cancer.
In contrast to this evidence, the carcinogenic risk of
fluoxetine was evaluated in three carcinogenicity studies
in rats and mice performed by the manufacturer (Eli
Lilly & Co.). In these studies, fluoxetine was given over a
period of 24 months in doses up to 10 mg/kg (Bendele
et al. 1992), without any signs of treatment-related neo-
plasm development. However, in a different study in
male rats, administration of 10 mg/kg i.p. fluoxetine did
not affect resting serum prolactin levels but strongly po-
tentiated stress-induced prolactin release (Krulich 1975).Epidemiological evidence
To date, the clinical relevance of these effects in the safety
assessment of antidepressant drugs has not been com-
pletely elucidated with regard to the risk of breast cancer
development or recurrence. There is epidemiologic evi-
dence that long-term use of the modern antidepressant
drugs may be associated with a higher risk for developing
breast cancer: In a case–control study using data from the
Ontario Cancer Registry and controls, the risk for cancer
development for long-term use of antidepressant drugs
was investigated (Cotterchio et al. 2000). Compared with
controls, use of tricyclic antidepressants for longer periods
(>2 years) was associated with an elevated risk of breast
cancer development (adjusted OR = 2.1, 95% CI 0.9-5.0),
however, this increase in risk lacked statistical significance.
Of the six most commonly reported antidepressant medi-
cations, only paroxetine use was associated with an
increase in breast cancer risk (adjusted OR = 7.2, 95%
Cl 0.9-58.3).
The Women’s Health Study (Kato et al. 2000) was per-
formed in 15,270 women who participated in a mammo-
graphic screening programme. During an average of 7.3
years of follow-up, 566 incident cases of breast cancer
were detected. The use of any type of psychotropic
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increased relative risk of 1.39 (95% CI 1.11-1.74).
A follow-up case–control study using a larger sample
from the same registry was performed by Steingart et al.
(Steingart et al. 2003). In this study of 3,077 breast can-
cer patients, 441 used antidepressants; controls included
2,994 patients without breast cancer diagnosis, including
372 with antidepressant treatment. The analysis showed
a significantly increased unadjusted risk for breast can-
cer for patient with ‘ever’ use of antidepressants (OR
1.17, 95% CI 1.01 – 1.36), especially for SSRI use (OR
1.33 (95% CI 1.07-1.66). Among the SSRIs, sertraline
showed a significantly increased risk (OR 1.58 (95% CI
1.03-2.41) and paroxetine a borderline increased risk
(OR 1.55, 95% CI 1.00-2.40). However, when risk was
adjusted for other confounding factors associated with
breast cancer risk, significance was lost, although the
point estimates remained more or less the same.
In a large retrospective cohort study of 109,004 female
health plan members who used various antidepressants
between 1995 and 2000, paroxetine use was evaluated
against breast cancer risk (Haque et al. 2005), where it
was shown that the age-adjusted relative risk (RR) com-
paring “ever” users of paroxetine with other antidepres-
sants was 1.12 (95% CI 0.96–1.31). Women who used
paroxetine for 2 or more years did not show an in-
creased risk of breast cancer compared to women who
used it for a shorter period. Furthermore, use of SSRIs
in general did not result in a statistically increased risk
(RR 1.14 (95% CI 0.87-1.49)).
Results from another hospital-based case–control study
(Kelly et al. 1999) in 5,814 women with breast cancer,
5,095 patients with other malignancies and 5,814 women
without malignancies, researchers investigated the relative
risk for developing breast cancer with regular use of anti-
depressants and structurally similar drugs. Though no sig-
nificant increases in risk for any category of regular use
were noted, the relative risk estimate for regular SSRI use
in the previous year, 1.8, was of borderline statistical sig-
nificance (95% confidence interval: 1.0, 3.3).
In a third case–control study, use of antidepressant
drugs was investigated in patients with invasive breast
cancer (n = 938) and controls (n = 771) (Moorman et al.
2003). Overall, women with invasive breast cancer did
not report antidepressant use more frequently than con-
trols (OR 1.0; 95% CI: 0.7-1.2). However, there was a
trend that SSRI use for 36 months or longer was more
prevalent in breast cancer patients than in controls (OR
2.2, 95% CI 0.8-6.3). Interestingly, carcinoma in situ
cases reported antidepressant use significantly less fre-
quently than controls (OR 0.6; 95% CI 0.4–0.8).
Another population-based case–control study included
975 elderly breast cancer cases and 1,007 age- and
residence-matched controls conducted in WashingtonState (Chien et al. 2006). Antidepressant use information
was obtained by structured in-person interviews. Over-
all, no association between ever use of antidepressants
and breast cancer risk was noted (OR 1.2, 95% CI 0.9–
1.6). However, compared to never users, ever SSRI users
had significantly elevated risks of progesterone receptor
(PR) negative and oestrogen receptor (ER) positive/PR-
negative breast cancers (OR 1.8, 95% CI 1.1–3.6 and OR
2.0, 95% CI 1.1–3.8, respectively), but not of tumours
with other hormone receptor profiles.
Contradicting results were obtained in a recent
population-based study in 2,908 incident breast cancer
cases and 2,927 control women (Wernli et al. 2009).
There was no increased breast cancer risk in patients
who received antidepressant drugs (OR 0.89, 95% CI
0.78-1.01).
In a large, retrospective cohort study based on pre-
scription fillings by breast-cancer free women, (Wang
et al. 2001), 38,273 females taking any antidepressant
drug were compared to 32,949 women who took any
other medication between 1989–1991. Use of anti-
depressant drugs was unrelated to the development of
breast cancer (HR 1.04, 95% CI 0.87-1.25).
Coogan et al. (Coogan et al. 2008) used data from 820
invasive breast cancer cases in a case–control study and
compared it to 2,852 hospitalised controls. The OR for all
breast cancer cases was not elevated among regular users
of SSRIs (OR 0.89, 95% CI 0.62-1.29). The results of this
study were confirmed in 2,138 patients with invasive
breast cancer and 2,858 controls (Coogan et al. 2005). The
OR was 1.1 (95% CI 0.8-1.7) for regular use of SSRIs and
0.7 (95% CI 0.4-1.5) for use of 4 or more years. No ORs
were elevated for any specifically-investigated SSRI.
Finally, this finding was again confirmed by a recent
population-based case–control study in 2,129 women with
primary invasive breast cancer and 21,297 randomly-
selected control women (Ashbury et al. 2012). In this large
study, no conclusive evidence of an increased breast
cancer risk associated with the use of SSRIs was found, in-
dependent of the degree of serotonin reuptake inhibition
or duration of use.
Discussion and Conclusion: Epidemiological studies,
especially register-based ones, do rarely control for all of
the possible confounding factors. Therefore, they do not
prove a potential causal relationship. However, they may
raise attention for possible associations and may motivate
to perform a prospective study. Therefore, prospective
long-term studies are needed to finally judge the risk of
antidepressant treatment and breast cancer development.
Interaction with tamoxifen
Fluoxetine and paroxetine, and to a much lesser extent,
possibly sertraline, citalopram and escitalopram, are
inhibitors of the cytochrome P450 isoform CYP2D6
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Looper 2009; Desmarais & Looper 2010) that is import-
ant for metabolising tamoxifen, the therapy of choice in
the adjuvant hormonal treatment of patients with
oestrogen receptor-positive breast cancer. As a pro-drug,
its active metabolite, endoxifen, is formed by a CYP2D6-
mediated reaction (Pritchard 2010). SSRIs and, in par-
ticular, fluoxetine and paroxetine as the strongest
CYP2D6 inhibitors, may therefore prevent the formation
of the active metabolite from inactive tamoxifen (Crewe
et al. 1997; Desta et al. 2004) and put breast cancer pa-
tients under anti-oestrogenic treatment at an increased
risk of breast cancer recurrence (Singh et al. 2011). This
was suggested by a population based cohort study in 2,430
women (Kelly et al. 2010), where the importance of
CYP2D6 inhibition by SSRI could clearly be demonstrated.
For paroxetine, the risk of death from breast cancer in-
creased significantly with the proportion of time that tam-
oxifen was given concomitantly with paroxetine.
No increase in recurrence risk (OR 1.1, 95% CI 1.1-
1.7) was demonstrated by a recent case–control study
for citalopram and its S-isomer in 732 Danish patients
who received tamoxifen for at least one year (Lash et al.
2011a; Lash et al. 2011b). This result may reflect the low
inhibitory potency of citalopram and escitalopram. On
the other hand, the lack of effect of citalopram or other
SSRIs may be also due to the small number of patients
who were studied in each of the subgroups.
In a recent matched case–control study in 3,901 breast
cancer survivors (Goetz et al. 2013), patients were
treated over 5 years either with tamoxifen alone, or after
initial treatment with tamoxifen for 2 years, were
switched to anastrozole, an aromatase inhibitor, which is
neither a pro-drug nor metabolised by cytochrome
CYP2D6. Homozygote-poor metabolisers for CYP2D6
tended to have a higher rate of breast cancer recurrence
with continued tamoxifen use (OR 2.40; 95% CI 0.86-
6.66, p = 0.09).
In a recent meta-analysis (Zeng et al. 2013), 20 clinical
trials (11,701 breast cancer patients) were included
where the impact of CYP2D6 polymorphisms on tam-
oxifen efficacy was assessed. Extensive metabolisers were
associated with significantly improved disease-free sur-
vival (HR 1.37; 95% CI 1.12-1.69; p = 0.002) and overall
survival (HR 1.25; 95% CI 1.03-1.50; p = 0.021).
On the basis of the available data, there is some
evidence that co-administration of SSRIs (at least of
fluoxetine and paroxetine) with tamoxifen may result in
an increase in breast cancer recurrence in patients with
anti-oestrogen therapy. Since alternative drugs are avail-
able that do not interact with CYP2D6, such combina-
tions should be avoided (Binkhorst et al. 2013). In
addition, pheno- or genotyping of patients for CYP2D6
poor metaboliser status may be warranted.Natural remedies and complementary medicine
In 2004, Fugate and Church assessed the efficacy and
safety of non-hormonal, non-oestrogen treatments of
menopause-associated vasomotor symptoms in a sys-
tematic review (Fugate & Church 2004). This review
included non-prescriptional (dietary isoflavones, vitamin
E, black cohosh, dong quai, evening primrose oil, physical
activity, phytoestrogens, and red clover) as well as pre-
scriptional treatments (clonidine hydrochloride, gabapen-
tin, methyldopa, mirtazapine, propranolol hydrochloride,
selective serotonin-reuptake inhibitors (SSRIs), and venla-
faxine. However, in contrast to the present review, studies
in cancer patients were explicitly excluded.
Vitamin E
The efficacy of vitamin E in treating climacteric symp-
toms was investigated by Ziaei and colleagues using 400
IU/d softgel vitamin E tablets. They reported signifi-
cantly reduced HF frequency (5.00 ± 3.34 vs. 3.19 ± 2.74)
and severity scores (2.37 ± 0.74, 1.80 ± 0.87) when com-
pared to placebo (p < 0.0001) (Ziaei et al. 2007).
The effects of vitamin E (800 IU daily) and placebo
were studied over 4 weeks by Barton in a randomised,
placebo-controlled, cross-over design in 120 breast can-
cer survivors. Although vitamin E preparations reduced
the frequency of HF significantly compared to placebo
in patients with a history of breast cancer and mild
symptoms, the magnitude of the effect was small (one
HF less per day), and therefore not clinically relevant
(Barton et al. 1998).
Phyto-oestrogens and vasomotor symptoms
The effects of phyto-oestrogens, plant-based compounds
that exert oestrogen-like effects, on vasomotor meno-
pausal symptoms were assessed in two Cochrane reviews
in 2007 and 2013 (Lethaby et al. 2007; Lethaby et al.
2013). The more recent meta-analysis comprised 43
randomised controlled trials with a total of 4364 partici-
pants, however trials with breast cancer survivor had
been excluded. Thirty-three of them have also been in-
cluded in our review. Ten studies were excluded since
they did not contain detailed information on HF
frequency and/or severity or dealt with (mixed) dietary
rather than pharmacological interventions. Certain trials
found that some phyto-oestrogen treatments in peri-
and post-menopausal women evoked a slight improve-
ment in the frequency and severity of HF and night
sweats when compared to placebo (Albertazzi et al.
1998; Scambia et al. 2000; Han et al. 2002; van de Weijer
& Barentsen 2002; Jeri 2002; Sammartino et al. 2003;
Nahas et al. 2004; Nahas et al. 2007; Khaodhiar et al.
2008; Cheng et al. 2007; Radhakrishnan et al. 2009; Ye
et al. 2012; Aso et al. 2012; Mainini et al. 2013; D'Anna
et al. 2007; D'Anna et al. 2009; Ferrari 2009; Evans et al.
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Crisafulli et al. 2004; Labos et al. 2013). However, many
trials were small and confounded by a high risk of bias
and unusually high placebo effect. Also, other investiga-
tions showed either no or an inconclusive benefit from
soy isoflavone administration (Baber et al. 1999; Knight
et al. 1999; Upmalis et al. 2000; St Germain et al. 2001;
Burke et al. 2003; Faure et al. 2002; Campagnoli et al.
2005; Tice et al. 2003; Penotti et al. 2003; Secreto et al.
2004; Lewis et al. 2006). It is worth mentioning that the
study that used the highest dose of isoflavones (200 mg/d)
showed an exacerbation of HF symptoms (Levis et al.
2011). Those studies that compared phyto-oestrogens in
breast and prostate cancer survivors likewise showed no
conclusive evidence that phytooestrogen supplements
effectively reduce HF (Quella et al. 2000; Van Patten et al.
2002; Nikander et al. 2003; MacGregor et al. 2005; Sharma
et al. 2009). Under the heading, Phyto-oestrogens – Isofla-
vones (ISOF), Additional file 1 summarises the findings
from the latest Cochrane review on this topic.
Isoflavones and breast/prostate cancer recurrence
With regard to preventing recurrence in breast cancer sur-
vivors, the data on beneficial effects of phyto-oestrogens
are conflicting here as well. The inhibitory effect of enter-
olactone, a metabolite and marker of dietary lignans, on
human aromatase by mammalian lignans and isoflavonoid
phyto-oestrogens has been shown in vitro (Adlercreutz
et al. 1993; Adlercreutz 1995), though the protective
effects against breast cancer are only slight. It is not yet
known whether this is due to a healthy diet or indeed
evoked by the presence of dietary phyto-oestrogens
(Adlercreutz 2002a; Adlercreutz 2002b). The effect of diet-
ary phyto-oestrogen ingestion on the survival of breast
cancer patients was investigated in 1,140 patients (Buck
et al. 2011) by determining enterolactone for a median
follow-up of 6.1 years. Enterolactone levels correlated
positively with patient survival. The highest quartile of
serum enterolactones was associated with a significantly
reduced risk of death, but only in oestrogen receptor-
negative tumours (HR 0.27 (95% CI 0.08-0.87)). It has
been suggested that the high concentration of lignans in
vegetarians, by inhibiting aromatase (=oestrogen synthe-
tase) in peripheral and/or cancer cells and lowering
oestrogen levels, may play a protective role as antipromo-
tional compounds during growth of oestrogen-dependent
cancers (Adlercreutz et al. 1993).
However, it is noteworthy that genistein, the most preva-
lent isoflavone in soy, can stimulate breast cancer growth
and may interfere with the anti-tumour activity of tamoxi-
fen (Duffy & Cyr 2003). Likewise, the isoflavone, biochanin
A, may attenuate the effects of tamoxifen and the aroma-
tase inhibitor, letrozole (Du et al. 2012; Singh et al. 2012;
Ju et al. 2008).Melatonin
Chen et al. (Chen et al. 2014) studied the effect of mela-
tonin at a dose of 3 mg/d over 16 weeks on HF frequency
and severity in 95 breast cancer survivors in a double-
blind placebo-controlled RCT. There was, compared to
placebo, a significant improvement in subjects’ sleep qual-
ity, but no significant decrease in HF frequency or severity
between treatments.
Herbal supplements and vasomotor symptoms
Herbal supplements are widely used for vasomotor symp-
toms, with varying degrees of efficacy. Among the more
frequently studied are hops (Heyerick et al. 2006; Erkkola
et al. 2010), red clover (Hidalgo et al. 2005; Geller et al.
2009; Lipovac et al. 2012), flaxseed (Lewis et al. 2006; Colli
et al. 2012; Pruthi et al. 2012), St. John’s Wort (Hypericum
perforatum) (Al-Akoum et al. 2009; Abdali et al. 2010;
Uebelhack et al. 2006; Briese et al. 2007), evening primrose
(Oenothera biennis) (Farzaneh et al. 2013), French mari-
time pine bark (Pycngenol) (Yang et al. 2007; Kohama &
Negami 2013); Sibiric Rhubarb (Rheum rhaponticum)
(Heger et al. 2006; Kaszkin-Bettag et al. 2007; Kaszkin-
Bettag et al. 2009; Hasper et al. 2009), valerian root
(Valeriana officinalis) (Mirabi & Mojab 2013), Guaraná
(Paullinia cupana) (Oliveira et al. 2013), and magne-
sium (Park et al. 2011). Summaries of these studies can
be found in Additional file 1.
Black cohosh (Cimicifuga racemosa)
One of the most widely studied and efficacious phytophar-
maceuticals, CR (Cimicifuga racemosa L. Actaea racemosa
L., black cohosh), is a perennial medicinal plant native to
North America where it has been used for centuries in
indigenous medicine for the treatment of many varied
conditions. However, today’s sole accepted indications are
menopause-related neurovegetative and emotional symp-
toms. Black cohosh or Cimicifuga racemosa extracts
(CRE) are described in a 2003 monograph of the European
Scientific Cooperative on Phytotherapy (ESCOP) as a
pharmacologically-active treatment for climacteric symp-
toms (ESCOP Monographs 2003). Furthermore, in the
2010 community herbal monograph of the Committee on
Herbal Medicinal Products (HMPC) of the EMA (EMEA
2010), a well-established use status was granted. CREs are
registered as treatment for menopausal symptoms in
many European countries (among them, Austria, Belgium,
Czech Republic, Denmark, Finland, Germany, Hungary,
Sweden, Switzerland, and UK) and Australia, South Korea,
South Africa. In some countries (such as USA) CRE are
used as a food supplement.
A recent Cochrane meta-analysis (Leach & Moore
2012), comprising 16 RCTs and recruiting a total of
2027 women with climacteric complaints, investigated
CR for treating vasomotor symptoms. The authors point
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the studies, pooling of the results was not possible. They
state there is adequate justification for conducting more
studies on this topic, but summarise that there was
insufficient evidence to support the use of CR for meno-
pausal symptoms. The conclusions of the authors, how-
ever, have been recently questioned by Beer et al. (Beer
et al. 2013) who criticised that the selection of clinical
studies in the Cochrane meta-analysis was biased. Not
even half of the selected 16 studies were conducted
within the indication using authorised products and
several positive clinical studies were excluded or not
identified (Osmers et al. 2005; Stoll 1987; Wuttke et al.
2003; Schellenberg et al. 2012). Using a re-analysis of all
appropriate placebo-controlled clinical studies, they ob-
tained a standardised mean difference of 0.385 in favour
of CR (p < 0.0001).
Randomised, controlled trials that have shown a
pharmacological effect and meeting the strict require-
ments of the FDA and EMA (FDA. U.S. Department of
Health and Human Services Food and Drug Administra-
tion 2003; EMEA. Committee for Medicinal products for
human use (CHMP) 2005), including at least 12 weeks
duration, have been undertaken with CRE in 19 clinical
studies among healthy menopausal women (Drewe et al.
2013; Lopatka et al. 2007; Vermes et al. 2005; Liske et al.
2002; Frei-Kleiner et al. 2005; Schellenberg et al. 2012;
Osmers et al. 2005; Ross 2012; Newton et al. 2006; Geller
et al. 2009; Stoll 1987; Wuttke et al. 2003; Nappi et al.
2005; Bai et al. 2007; Uebelhack et al. 2006; Briese et al.
2007; Oktem et al. 2007) and in breast cancer survivors
(Hernández Munoz & Pluchino 2003; Rostock et al. 2011).
Four other studies (Huang et al. 2013; Pockaj et al. 2004;
Jacobson et al. 2001; Pockaj et al. 2006) did not meet the
12-week criterion, and can thus just be considered as sup-
portive research, though for thoroughness, they are also
cited in Additional file 1.
Various doses of ethanolic and isopropanolic formula-
tions of CRE have been investigated in menopausal
women (Drewe et al. 2013; Lopatka et al. 2007; Vermes
et al. 2005; Liske et al. 2002) and results showed a signifi-
cant decrease in HF symptoms and scores. When com-
pared to placebo (Frei-Kleiner et al. 2005; Schellenberg
et al. 2012; Osmers et al. 2005; Ross 2012), similarly posi-
tive results were observed. When combined or compared
with other actives (Newton et al. 2006; Geller et al. 2009;
Stoll 1987; Wuttke et al. 2003; Nappi et al. 2005; Bai et al.
2007; Uebelhack et al. 2006; Briese et al. 2007; Oktem
et al. 2007; Huang et al. 2013), CRE was at least as effica-
cious as the other compound(s), except in (Newton et al.
2006) where herbal regimens did not reduce vasomotor
symptoms.
Studies have also been conducted in breast cancer sur-
vivors using CRE alone (Pockaj et al. 2004), where HFwere reduced by half; CRE vs. placebo (Jacobson et al.
2001; Pockaj et al. 2006) where no significant difference
was achieved, and CRE with tamoxifen (Hernández
Munoz & Pluchino 2003; Rostock et al. 2011), where
again, significant improvements were noted.
Mechanism of action of CR
CR’s mechanism of action on climacteric symptoms is
not yet clear. Selective modulation of oestrogen recep-
tors, serotonergic, antioxidant and anti-inflammatory ef-
fects have been proposed (Ruhlen et al. 2008). CR binds
to the serotonin receptors, 5-HT1A, 5-HT1D and 5-HT7
(Burdette et al. 2003; Powell et al. 2008). From these, 5-
HT1A and 5-HT7 are also expressed in the hypothalamus
and are involved in thermoregulation (Burdette et al.
2003; Hedlund et al. 2003; Naumenko et al. 2011).
There are conflicting data as to whether CREs act as
phyto-oestrogens. Early studies in uterine and pituitary
cells of ovariectomised rats showed that a chloroform
fraction from a methanolic CRE did bind to oestrogen
receptors (ER) (Jarry et al. 1985). Another study showed
some evidence for an oestrogenic effect of CR in mice
and oestrogen-dependent human breast cancer MCF-7
cells (Liu et al. 2001a). Partly contradicting these find-
ings, the same group showed that CRE did not alter
expression of different oestrogen-inducible genes (e.g.,
presenelin-2, progesterone receptor) (Liu et al. 2001b).
Later studies showed that a CRE did not bind to the
oestrogen receptors Erα and ERβ (Jarry et al. 2003).
Gene expression analysis showed that treatment with
CREs down-regulates the expression of Erα (Gaube et al.
2007). The lack of an oestrogenic effect of CREs may be
partly explained by an inhibition of the local oestrogen
synthesis in breast tissue (Stute et al. 2007) or inhibition of
the conversion of oestrone sulphate to active oestradiol in
MCF-7 and MDA-123 breast cancer and human granulosa
lutein cells (Rice et al. 2007). Furthermore, in MCF-7 cells,
repetitive administration of CRE lead-induced gene
expression opposite to 17β-oestradiol and more similar to
tamoxifen (Gaube et al. 2007).
Two studies from the same group showed weak
oestrogenic effects (e.g., lowering of LH secretion, bone re-
modelling, vaginal mucosa) in menopausal women and
ovarectomised rats (Düker et al. 1991; Wuttke et al. 2006).
However, most recent studies confirm the absence of any
oestrogenic effect: In an oestrogen-sensitive fish (Japanese
medaka), Zang et al. (Zhang et al. 2003) showed that, in
contrast to the phyto-oestrogen genistein and oestradiol,
CRE and some of its constituents (e.g., cimiracemoside A,
25-O-methyl-cimigenoside, actein, 26-deoxy-actein) did not
change oestrogenic activity. In transcriptional-activation
assays in yeast in oestrogen-dependent S. cerevisiae strain
PL3, an isopropanolic extract (40%) did not show any
oestrogenic activity (Pockaj et al. 2004).
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placebo were administered to 351 patients in a 1-year,
double-blind, placebo-controlled RCT (HALT-Study,
Herbal Alternatives for Menopause (Reed et al. 2008))
study. After 12 and 52 weeks treatment, the HT group
had a lower percentage of parabasal cells and vaginal
dryness than did the placebo group (p < 0.05). Abnormal
bleeding was reported in 16.9% of women. When used
alone or as part of a multi-botanical product with or with-
out soy dietary changes, CR exerted no effects on vaginal
epithelium, endometrium, or reproductive hormones, indi-
cating no local or systemic oestrogenic effects in patients.
CR’s lack of clinically-significant oestrogenic effects
was further concluded by a lack of change in vaginal cy-
tology and corresponding sexual hormones during 24-
weeks of treatment in 152 peri- and post-menopausal
women (Liske et al. 2002) where CRE treatment signifi-
cantly reduced the frequency and severity of HF. These
finding were corroborated by several other clinical stud-
ies, where the absence of systemic oestrogenic effects of
CREs on sexual hormones and/or vaginal or endometrial
thickness have been described (Nappi et al. 2005; Liske
et al. 2002; Düker et al. 1991; Wuttke et al. 2006; Ruhlen
et al. 2007; Rauš et al. 2006; Reed et al. 2008).
In vitro effects of CREs on cell proliferation in oestrogen-
dependent breast cancer cells
The effect of CREs on human oestrogen receptor-positive
and –negative breast cancer cell lines has been tested in
different in vitro experiments where the results are often
contradictory. The majority of published studies were able
to show an inhibition of proliferation, or no effect, of
CREs on cell proliferation.
The growth of oestrogen-dependent human breast
cancer MCF-7 cells was not stimulated after a 48-hour
treatment with an alcoholic CRE (Amato et al. 2002). An
inhibitory effect on cell proliferation of oestrogen
receptor-positive human mammary carcinoma cell lines
was shown for the mammary carcinoma cell line 435
(Neßelhut et al. 1993), the human breast adenocarcinoma
MCF-7 cells (Bodinet & Freudenstein 2002; Bodinet &
Freudenstein 2004; Zierau et al. 2002; Garita-Hernandez
et al. 2006; Al-Akoum et al. 2007; Rice et al. 2007; Gaube
et al. 2007), T47D cells (Zava et al. 1998; Dixon-Shanies &
Shaikh 1999), the ER−Her2 over-expressing breast cancer
cell line MDA-MB-453 (Einbond et al. 2004; Einbond
et al. 2006), EMT6 mouse mammary tumour cells
(Rockwell et al. 2005) and MDA-MB-231 cells, which are
associated with a highly-invasive potential (Al-Akoum
et al. 2007; Hostanska et al. 2007; Rice et al. 2007).
CREs, or partly-isolated triterpene constituents of CREs,
inhibited oestrogen-stimulated proliferation (Bodinet &
Freudenstein 2004; Zierau et al. 2002; Al-Akoum et al.
2007) and enhanced the effects of tamoxifen (Bodinet &Freudenstein 2004; Al-Akoum et al. 2007), 5-fluorouracil,
paclitaxel, doxorubicine and docetaxel (Rockwell et al.
2005; Einbond et al. 2006) in breast cancer cells.
This anti-cancer effect has been confirmed for some of
the constituents of CR (Einbond et al. 2008). Among
them, actein (β-D-xylopyranoside) showed an IC50 of 8.4
μM for the inhibition of growth of Her2 overexpressing
MDA-MB-453 cells and of 32.5 μM for Her2 transfected
and 45.8 μM for parenteral cells. Actein treatment al-
tered the actin filament distribution of, and induced
apoptosis in, these cells.
The mechanisms of the anti-proliferating effects have
not yet been identified. However, modulation of cyclin
D1 promoter activity and transcription activity of the
p21 gene promoter may be involved (Garita-Hernandez
et al. 2006). Changes in the gene expression pattern dur-
ing chronic treatment with CRE have been investigated
in MCF-7 cells in comparison with oestradiol and tam-
oxifen (Gaube et al. 2007). The pattern of gene induction
was opposite to oestradiol and more similar to tamoxi-
fen. Induced genes exhibited an antiproliferative and
apoptosis-sensitising manner, as well as an increase in
mRNAs coding for gene products involved in several
stress response pathways.
Beyond those effects related to acute or sub-chronic
administration, CRE may exert a chemopreventive effect.
Treatment of rats starting from 56 weeks of age for 40
weeks resulted in a dose-dependent reduction of mam-
mary adenocarcinomas (Einbond et al. 2012). This effect
may be related to the observed reduced Ki-67 and cyclin
D1 protein expression in fibroadenomas.CR and tumour cell growth
It has been reported that inhibition of proliferation and
induction of apoptosis are due to the action of triterpene
glycosides and the cinnamic acid esters contained in
CREs (Hostanska et al. 2004a; Hostanska et al. 2004b).
In a further in vitro test for invasive potential of highly-
invasive oestrogen receptor-negative MDA-MB 231 hu-
man breast cancer cells, 5 μg/ml doses of triterpene
glycosides and the cinnamic acid esters reduced cell
invasion by 34% and 25.5%, respectively (Hostanska
et al. 2007). Similar results were obtained by Lupu et al.
(Lupu et al. 2003). For various CREs (hexane, ethyl acetate
and water), no oestrogenic activity (growth induction,
regulation of oestrogen-dependent gene expression) has
been demonstrated. In addition, anchorage-independent
growth was investigated in oestrogen receptor positive
MCF7 and T47D cells; thereby indicating possible pro-
gression of early stage breast cancer to a more aggressive
state and the potential to build metastases (Mori et al.
2009). CR did not stimulate anchorage-dependent growth
of breast cancer cells (Lupu et al. 2003).
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shown in oestrogen-sensitive MCF-7 cells. Tamoxifen
stimulated the growth of MCF-7 cells at high concentra-
tions; on the other hand, when given alone, inhibited
oestrogen-induced cell growth in a dose-dependent
manner. Contrasting to these results, CR did not stimu-
late MCF-7 cell growth when given alone and blocked
oestrogen-induced cell growth dose-dependently. The
combination of tamoxifen with CR showed an enhanced
(synergistic) cytotoxic effect of CR. It also inhibited
growth of oestrogen-independent MDA-MB-231 breast
cancer cells and this effect was synergistically enhanced
by tamoxifen in a dose-dependent manner (Al-Akoum
et al. 2007).
After acute administration of a CRE (at a dose of 6,
60, or 600 mg/kg) to mice, no signs of an oestrogenic ef-
fect could be detected (Einer-Jensen et al. 1996). Due to
different oestrogenic effects of an isopropanolic CRE in
various organs in ovariectomised rats, a selective
oestrogen receptor modulator (SERM) activity has been
postulated (Seidlová-Wuttke et al. 2003).
Stimulatory effects on tumour proliferation were stud-
ied in an in vivo oestrogen-receptor positive breast can-
cer model (Freudenstein et al. 2002), where mammary
tumours were induced by 7,12-dimethylbenz[a]anthra-
cene administration in female rats. After ovariectomy,
growth of hormone-dependent mammary tumours was
not stimulated by an isopropanolic CRE or placebo given
over 6 weeks in contrast to animals treated with 450 μg/
kg/day of the oestrogen, mestranol. Furthermore, there
was neither a direct effect on uterine tissue proliferation
nor an indirect effect on pituitary-secreted, oestrogen-
regulated hormones exerted by the CRE.
The effect of CRE on in vivo tumour growth was
further investigated in RUCA-I rats, an endometrial
adenocarcinoma model. In contrast to tamoxifen,
there was no stimulation of ectopic growth or an in-
crease in the metastasising potential of the primary
tumour noted with CR (Nisslein & Freudenstein
2004).
However, in contrast to the above investigations,
one study using transgenic mice expressing c-erbB2
(MMTV-neu mouse model), showed that CRE signifi-
cantly increased the incidence of lung metastases in
tumour-positive animals when compared to mice fed a
control diet free of isoflavones. Interestingly, no effect
of CR on mammary tumour development was ob-
served. This shows that CRE did not influence breast
cancer risk if given prior to tumour formation (Davis
et al. 2008). However, the literature indicates that
these results have not been either confirmed nor re-
futed by other groups nor is supporting evidence avail-
able from clinical studies in patients with breast
cancer.CR and cytochrome P450 interaction
In vitro experiments using human liver microsomes sug-
gested that methanolic extracts of CR significantly in-
hibit several cytochrome isoforms (IC50: CYP2B6: 49.2
μg/ml, CYP2C19: 23.9-36.3 μg/ml, and CYP2E1: 11.5
μg/ml) (Sevior et al. 2010). In a human interaction study,
CR (80 mg) was given over 14 days to 19 healthy sub-
jects. No clinically relevant interaction with CYP3A4
could be demonstrated using midazolam as the test drug
(Gurley et al. 2006a). In MDA-MB-453 and MCF-7
human breast cancer cells, CYP1A1, CYP1B1 (Einbond
et al. 2007; Gaube et al. 2007) and ABCC3 (MRP3)
(Einbond et al. 2007) were up-regulated. One in vitro
study showed that a CRE inhibited the formation of tam-
oxifen metabolites by CYP3A4 and CYP2D6, with IC50
values of 16.5 and 50.1 μg/mL, respectively. Eight triterpene
glycosides were also identified as competitive CYP3A4
inhibitors, with IC50 values ranging from 2.3-5.1 μM, and
protopine and allocryptopine alkaloids were shown to be
competitive CYP2D6 inhibitors, with Ki values 78 and
122 nM, respectively (Li et al. 2011).
In 12 healthy volunteers, only a low, but clinically not
relevant, interaction potential was shown for CYP2D6
when CR was given over 28 days (Gurley et al. 2005). The
lack of an interaction of CR with CYP3A4, CYP2D6 and
ABCB1 (P-glycoprotein) was confirmed in four separate
human studies in healthy volunteers (Gurley et al. 2005;
Gurley et al. 2006a; Gurley et al. 2008; Gurley et al. 2006b).
Although there is evidence for an interaction potential
of CR and its constituents with tamoxifen metabolism,
the clinical data nevertheless indicate that there is no
relevant inhibition of CYP2A4 or CYP2D6. Therefore, a
clinically relevant interaction of CR with tamoxifen is
most unlikely.
Clinical effects of CR with regard to tumour development
Three notable studies assess breast density measure-
ments as a biomarker for the risk of breast cancer
development.
In a large prospective, open study in 400 post-
menopausal women, the endometrial safety and breast
density were studied before and after a 52-week CRE
treatment (Rauš et al. 2006). No case of hyperplasia oc-
curred and no serious adverse endometrial outcomes
were found, indicating endometrial safety. Endometrial
thickness, measured by endovaginal ultrasonography,
did not increase during treatment. An increase in breast
density was found in only one woman who was diag-
nosed with invasive breast cancer which, based on his-
tory, was unrelated to the CR.
In the second trial, the influence of CR on mammary
breast density was investigated in a prospective, open,
uncontrolled safety study in 74 post-menopausal women
(Hirschberg et al. 2007). Breast density was assessed by
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needle aspiration histology using Ki-67/MIB-1 monoclo-
nal antibody. Assessment performed at baseline and
after 24 weeks showed no increase in mammographic
breast density or breast cell proliferation.
Lundström confirmed these results by comparing two
studies (Lundström et al. 2011): The first, a prospective,
open, uncontrolled drug safety study in 65 post-
menopausal women who were treated with 20 mg CR
twice daily and the second, a randomised, placebo-
controlled clinical study in 154 post-menopausal women
who were treated with either oestradiol 2 mg/norethis-
terone acetate 1 mg (E2/NETA), tibolone 2.5 mg or pla-
cebo. Mammograms were performed at baseline and
showed comparable breast density for each treatment.
Renewed mammograms after 24 weeks of treatment
showed that both E2/NETA and tibolone significantly
increased breast density (14.3%, and 2.3%, respectively,
both p < 0.001) while CR and placebo had no effect on
breast density. These differences were highly significant
(p < 0.0001) (Lundström et al. 2011).
In a study evaluating 149 patients, two doses (39 and
127.3 mg/d) of an isopropanolic CRE were studied in a
double-blind RCT for the treatment of climacteric symp-
toms over a 24-week period (Liske et al. 2002). Compared
to baseline, both treatments significantly decreased cli-
macteric symptoms, but no oestrogen-induced change in
vaginal mucosal thickness or sex hormones were observed,
indicating a lack of local and overall oestrogenic effects.
In a retrospective case–control study (Rebbeck et al.
2007), use of CRE was associated with a significantly
lower risk of developing breast cancer (adjusted OR
0.39; 95% CI 0.22-0.70), however, the sub-sample of pa-
tients treated with CR was rather small. Similar results
were found in a large German case–control study in
10,121 post-menopausal women (Obi et al. 2009), where
3,464 incident breast cancer cases were compared to
6,657 controls. Ever use of isopropanolic CRE was asso-
ciated with a borderline reduced risk for the develop-
ment of breast cancer (OR 0.80; 95% CI 0.63-1.00). No
protective effect of CR (HR 1.17; 95% CI 0.75-1.82) was
seen in a large case–control study (Brasky et al. 2010)
in 35,016 post-menopausal women, however, the num-
ber of incident breast-cancer cases in the CR sub-
population was too small (n = 21) to allow a meaningful
conclusion.
The risk of breast cancer recurrence where the
primary outcome was disease-free survival was investi-
gated in 18,861 patients having a previous breast cancer
diagnosis (Heinecke-von Zepelin et al. 2007), among
whom 1,102 patients received isopropanolic CRE for a
mean overall observation period of 3.6 years. Controlling
for age, tamoxifen use and other confounders, the Cox
regression model demonstrated a statistically significantprotective effect of isopropanolic CR on recurrence rate
(HR 0.83, 95% CI 0.69-0.99).
Males
Several studies have shown that those anti-androgen
treated, or surgically castrated, men who develop severe
HF symptoms respond well to treatments that are effective
against menopausal symptoms in women, in particular,
oestrogens, though often accompanied with breast tender-
ness, gynaecomastia and an increased risk of cardiovascu-
lar and thrombembolic events (Adelson et al. 2005).
Alternatively, in vitro experiments indicate that treat-
ment with CREs may benefit prostate cancer patients.
Anti-proliferative effects of CR for several prostate can-
cer cell lines and in vivo tumours have been observed.
Most studies describe induction of apoptotic cellular re-
sponse and subsequent reduction in proliferation and
partly prostate-specific antigen secretion in androgen
dependent tumour cells (LNCaP) (Hostanska et al. 2005;
Jarry et al. 2007; Jarry et al. 2005). In addition, 5α-
reductase (the key enzyme for dihydro-testosterone syn-
thesis) was inhibited by CR in the rat prostate (Seidlová-
Wuttke et al. 2006), possibly indicating its suitability in
preventing and treating prostate cancer and benign pros-
tate hyperplasia.
Further, one study showed in vivo anti-proliferative and
growth inhibitory effects for implanted prostate cancer in
immunodeficient (nu/nu) athymic nude mice (Seidlova-
Wuttke et al. 2006). However, a controlled clinical trial is
yet to be performed.
Discussion
The most effective treatment of climacteric symptoms is
HT with oestrogen or a combination of oestrogen and
progestins (MacLennan et al. 2009). However, the bene-
fits are partly outweighed by a significantly increased
risk for the development of breast cancer (Collaborative
Group on Hormonal Factors in Breast Cancer 1997;
Porch et al. 2002; Rossouw et al. 2002; Weiss et al. 2002;
Beral et al. 2002; Beral & Million Women Study Collab-
orators 2003; Chlebowski et al. 2009). After publication
of the WHI studies (Rossouw et al. 2002) and the
Million Women Study (Beral & Million Women Study
Collaborators 2003), HT use decreased drastically
worldwide (Hersh et al. 2004; Canfell et al. 2008;
Antoine et al. 2011), accompanied by a significant de-
crease in breast cancer incidence (Canfell et al. 2008;
Ravdin et al. 2007; Canfell et al. 2009).
Recently, the risk-benefit ratio of HT was reassessed
for various ages and time intervals since menopause on-
set. The North American Menopause Society (NAMS)
(NAMS 2012) proposed that duration of treatment
should be limited to younger women up to the age of 50
to 59 years; beyond which, HT is associated with
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the International Menopause Society (IMS) in 2011
(Sturdee et al. 2011), which considered HT as a first-line
therapy choice for climacteric symptoms. Finally, a glo-
bal consensus on the use of HT was obtained by The
American Society for Reproductive Medicine, The Asia
Pacific Menopause Federation, The Endocrine Society,
The European Menopause and Andropause Society, The
International Menopause Society, The International
Osteoporosis Foundation and The North American
Menopause Society (de Villiers et al. 2013). They stated
that HT “is the most effective treatment for vasomotor
symptoms associated with menopause at any age, but
benefits are more likely to outweigh risks for symptom-
atic women before the age of 60 years or within 10 years
after menopause”. Although some HT restrictions have
been withdrawn, there is still a considerable need for
non-hormonal treatment alternatives, especially for eld-
erly post-menopausal women or cancer patients of both
genders. Therefore, this present work aimed to assess
the risk-benefit ratio of various non-hormonal treatment
options. Among them, four non-hormonal treatments
appear to have significant evidence for a beneficial effect
in treating vasomotor climacteric or androgen-ablation
symptoms, although some studied the effects over a
period shorter than 12 weeks: gabapentin/pregabalin
(Loprinzi et al. 2002a; Guttuso et al. 2003; Reddy et al.
2006; Loprinzi et al. 2007; Butt et al. 2008; Saadati et al.
2013; Agarwal et al. 2014; Pinkerton et al. 2014;
Loprinzi et al. 2010; Pandya et al. 2004; Pandya et al.
2005; Bordeleau et al. 2010; Loprinzi et al. 2009;
Moraska et al. 2010), SSRIs (Stearns et al. 2003; Stearns
et al. 2005; Simon et al. 2013; Huang et al. 2013;
Stearns et al. 2000; Gordon et al. 2006; Grady et al.
2007; Kerwin et al. 2007; Aedo et al. 2011; Kimmick
et al. 2006; Wu et al. 2009; Suvanto-Luukkonen et al.
2005; Oktem et al. 2007; Loprinzi et al. 2002b; Barton
et al. 2010; Barton et al. 2003; Defronzo Dobkin et al.
2009; Freedman et al. 2011; Freeman et al. 2011;
Carpenter et al. 2012; Ensrud et al. 2012), venlafaxine/
desvenlafaxine (Evans et al. 2005; Loprinzi et al. 2006;
Loprinzi et al. 1998; Carpenter et al. 2007; Quella et al.
1999; Loprinzi et al. 2000; Loibl et al. 2007; Buijs et al.
2009; Boekhout et al. 2011; Bordeleau et al. 2010;
Vitolins et al. 2013; Speroff et al. 2008; Archer et al.
2009a; Archer et al. 2009b; Cheng et al. 2013; Bouchard
et al. 2012; Pinkerton et al. 2013), and CREs (Drewe
et al. 2013; Lopatka et al. 2007; Vermes et al. 2005;
Liske et al. 2002; Frei-Kleiner et al. 2005; Schellenberg
et al. 2012; Osmers et al. 2005; Ross 2012; Newton
et al. 2006; Geller et al. 2009; Stoll 1987; Wuttke et al.
2003; Nappi et al. 2005; Bai et al. 2007; Uebelhack et al.
2006; Briese et al. 2007; Oktem et al. 2007; Huang et al.
2013; Pockaj et al. 2004; Jacobson et al. 2001; Pockajet al. 2006; Hernández Munoz & Pluchino 2003;
Rostock et al. 2011).
Randomised, controlled trials that have shown a
pharmacological effect and are at least 12 weeks dur-
ation, as required by FDA and EMA (FDA. U.S. Depart-
ment of Health and Human Services Food and Drug
Administration 2003; EMEA. Committee for Medicinal
products for human use (CHMP) 2005) have only been
undertaken for gabapentin (Guttuso et al. 2003; Reddy
et al. 2006); (Saadati et al. 2013) #3447 (Agarwal et al.
2014; Pinkerton et al. 2014); SSRIs: (Simon et al. 2013;
Aedo et al. 2011; Suvanto-Luukkonen et al. 2005; Oktem
et al. 2007), venlafaxine (Evans et al. 2005; Boekhout
et al. 2011; Vitolins et al. 2013), desvenlafaxine (Speroff
et al. 2008; Archer et al. 2009a; Archer et al. 2009b;
Cheng et al. 2013; Bouchard et al. 2012; Pinkerton et al.
2013), isoflavones (Albertazzi et al. 1998; Han et al. 2002;
van de Weijer & Barentsen 2002; Jeri 2002; Sammartino
et al. 2003; Nahas et al. 2004; Nahas et al. 2007; Khaodhiar
et al. 2008; Cheng et al. 2007; Radhakrishnan et al. 2009;
Ye et al. 2012; Aso et al. 2012; Mainini et al. 2013; D'Anna
et al. 2007; D'Anna et al. 2009; Ferrari 2009; Evans et al.
2011; Murkies et al. 1995; Crisafulli et al. 2004; Labos
et al. 2013; Upmalis et al. 2000; Faure et al. 2002); hops
(Heyerick et al. 2006); red clover (Hidalgo et al. 2005;
Lipovac et al. 2012), flaxseed (Colli et al. 2012), St. John’s
wort (Uebelhack et al. 2006; Briese et al. 2007), French
maritime pine bark (Yang et al. 2007; Kohama &
Negami 2013), Sibiric Rhubarb (Heger et al. 2006;
Kaszkin-Bettag et al. 2007; Kaszkin-Bettag et al. 2009;
Hasper et al. 2009), and CREs (Drewe et al. 2013;
Lopatka et al. 2007; Vermes et al. 2005; Liske et al.
2002; Frei-Kleiner et al. 2005; Schellenberg et al. 2012;
Osmers et al. 2005; Ross 2012; Newton et al. 2006;
Geller et al. 2009; Stoll 1987; Wuttke et al. 2003; Nappi
et al. 2005; Bai et al. 2007; Uebelhack et al. 2006; Briese
et al. 2007; Oktem et al. 2007; Hernández Munoz &
Pluchino 2003; Rostock et al. 2011).Conclusion
Several non-hormonal alternatives to hormonal therapy
have been established and confirmed for the treatment
of vasomotor climacteric symptoms in peri- and post-
menopausal women. Although there are indications that
these treatments are useful in patients with a history of
breast cancer, this still requires confirmation by larger
clinical trials.
This systematic analysis did not carry out any of its
own clinical research involving patients and the state-
ments relating to the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments
thus do not apply.
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